Document:

EX-10.13

 Exhibit 10.13 

Novation Agreement 
 This Novation
Agreement is dated as of 4th June 2014 
  

	(1)	HSBC Bank USA, National Association, a company organised under the laws of the United States of America (registered number 20-1177241) whose registered office is at 1800 Tysons Boulevard, Suite 50, McLean
Virginia 22102, United States, acting through its London Branch whose principle place of business is at 8 Canada Square, London E14 5HQ (the “Outgoing Party”) 

 

	(2)	HSBC Bank plc, 8 Canada Square, London E14 5HQ (the “Incoming Party”) 

  

	(3)	THE BANK OF NEW YORK MELLON as Trustee of the SPDR Gold Trust (the “Continuing Party”) 

(each a “Party” or collectively referred to as the “Parties”) 

Recitals: 
  

	(A)	The Outgoing Party and the Continuing Party are party to the Unallocated Bullion Account Agreement dated as of 1st June 2011 and the Allocated Bullion
Account Agreement dated as of 1st June 2011 (the “Contracts”). 

  

	(B)	As part of the transfer by the Outgoing Party to the Incoming Party of the Outgoing Party’s Precious Metals Custody and Clearing business, operated through the Outgoing Party’s London-based branch, in
an effort to promote operating efficiency, the Outgoing Party has transferred its business to the Incoming Party. As part of the business transfer, the Outgoing Party wishes to transfer by novation to the Incoming Party, and the Incoming Party
wishes to accept the transfer by novation of, all the rights, obligations, duties and liabilities of the Outgoing Party under and in respect of the Contracts to the Incoming Party with the effect that the Continuing Party and the Incoming Party
enter into new Contracts between them having identical terms to those of each old Contract. 

 AGREED TERMS 

 

	1.	NOVATION 

  

	1.1	The Outgoing Party will inform the Continuing Party of the date on which the novation of the Contracts are to occur pursuant to this Novation Agreement (the “Effective Date”) 30 days prior to the
Effective Date. From and including such Effective Date, the Outgoing Party shall transfer all its rights and obligations under the Contracts to the Incoming Party. 

 

	1.2	The Incoming Party shall enjoy all rights and benefits of the Outgoing Party under the Contract, and all references to the Outgoing Party in the Contracts shall be read and construed as references to the Incoming Party.

  

	1.3	The Incoming Party agrees to perform the Contracts and be bound by their terms in every way as if it were the original party to it in place of the Outgoing Party. 

 

	1.4	The Continuing Party agrees to perform the Contracts and be bound by their terms in every way as if the Incoming Party were the original party to it in place of the Outgoing Party. 

 RELEASE OF OBLIGATIONS AND LIABILITIES 

 

	2.1	In consideration of the mutual representations and releases of the Outgoing Party and the Continuing Party herein and the mutual obligations assumed herein by the Continuing Party and the Incoming Party and other good
and valuable consideration (the receipt and sufficiency of which are hereby acknowledged by each of the parties), the parties to this Novation Agreement hereby agree that, with effect from and including the Effective Date: 

 

	 	(i)	the Outgoing Party and Continuing Party are each released and discharged from further obligations to each other with respect to the Contracts, and their respective rights against each other thereunder are cancelled,
provided that such release and discharge shall not affect any rights, liabilities or obligations of the Continuing Party and Outgoing Party with respect to payments or other obligations due and payable or due to be performed on or prior to the
Effective Date, and all such payments and obligations shall be performed by the Continuing Party or the Outgoing Party in accordance with the terms of the Contracts; Notwithstanding the aforesaid, in the event the Outgoing Party fails to make any
payment or satisfy any obligation to the Continuing Party, the Incoming party shall make such payment and assume and satisfy such obligation; 

  

	 	(ii)	the Continuing Party and the Incoming Party each undertake liabilities and obligations towards the other and acquire rights against each other identical in their terms to each corresponding Contract (for the avoidance
of doubt, as if the Incoming Party were the Outgoing Party and the Continuing Party remaining the Continuing Party, save for any rights, liabilities or obligations of the Continuing Party or Outgoing Party with respect to payments or other
obligations due and payable or due to be performed on or prior to the Effective Date); and 

  

	 	(iii)	the Contracts will in all respects continue on their existing terms. 

 2.2 As of the Effective Date, the
Continuing Party should deal only with the Incoming Party in respect of the Contracts; all correspondence relating to payments should be sent to the Incoming Party at the following email address uk.metals.operations@hsbc.com, and marked for
the attention of Tony Dean, Manager Bullion Operations, telephone no. +44 (0) 207 991 9266. Any queries relating to the Contracts should be sent to the Incoming Party at the following HSBC Bank Plc, 8 Canada Square, London E14 5HQ, UK marked
for the attention of Don G Pearce, Client Documentation (telephone no. +44 (0) 207 992 2090). 
 If the Effective Date is deferred to another time, the
Outgoing Party will give notice of the deferral and new Effective Date to the Continuing Party (which may be in separate notices). 
  

	3.	REPRESENTATIONS AND WARRANTIES 

  

	3.1	Each Party represents and warrants on the date of this Novation Agreement and as of the Effective Date that: 

  

	 	(i)	it has the power to enter into, and has duly authorised the execution and delivery of, this Novation Agreement. 

  

	 	(ii)	its obligations hereunder constitute its legal, valid and binding obligations enforceable in accordance with their terms. 

  

	 	(iii)	all consents, licenses, approvals and authorisations of, or registrations and declarations with, any governmental or other authority required to be obtained by it with respect to this Novation Agreement has been
obtained or made and are valid and subsisting. 

  

	3.2	Each of the Outgoing Party and the Continuing Party represents and warrants to the Incoming Party on the date of this Novation Agreement and as of the Effective Date that: 

 

	 	(i)	it has made no prior transfer of any of its rights, obligations, title or interest under the Contracts; and 

	 	(ii)	facts or circumstances which would give rise to an insolvency or bankruptcy event have not occurred in relation to such party. 

  

	4.	COSTS AND EXPENSES 

  

	4.1	Each Party shall pay its own costs and expenses incurred in connection with the negotiation, preparation and execution of this Novation Agreement. 

 

	4.2	The Outgoing Party shall pay any stamp duty, and any other similar duties and taxes (if any) to which this Novation Agreement (and any documents referred to in it) or the transaction contemplated by this Novation
Agreement may be subject or give rise. 

  

	5.	COUNTERPARTS 

 This Novation Agreement (and each amendment, modification and waiver in respect of it) may
be executed and delivered in counterparts, each of which will be deemed an original. 
  

	6.	AMENDMENTS 

 No amendment, modification or waiver in respect of this Novation Agreement will be effective
unless in writing and executed by each of the Parties. 
  

	7.	GOVERNING LAW 

 This Novation Agreement and any dispute or claim arising out of or in connection with it
(including non-contractual disputes or claims) shall be governed by and construed in accordance with English law. 
 IN WITNESS WHEREOF the Parties have
executed this Novation Agreement on the respective dates specified below with effect from the date specified on the first page of this Novation Agreement. 

For and on behalf of 

			
	HSBC Bank USA, National Association
		
	By:	 	

		
	Name:	 	DON G. PEARCE
		
	Title:	 	AUTHORISED SlGNATORY
		
	Date:	 	
	
	For and on behalf of
	HSBC Bank plc
		
	By:	 	

		
	Name:	 	Marion Murdoch
		
	Title:	 	Authorised Signatory
		
	Date:	 	

 For and on behalf of 

THE BANK OF NEW YORK MELLON as Trustee of the SPDR Gold Trust

 

			
	 By:
	 	 

		
	 Name:
	 	 Thomas N O’ Donnell

		
	 Title:
	 	 Managing Director

		
	 Date:
	 	 8/20/14EX-10.1

 Exhibit 10.1 

$80,000,000 
 LEXICON
PHARMACEUTICALS, INC. 
 5.25% Convertible Notes Due 2021 

PURCHASE AGREEMENT 
 November 20,
2014 

 November 20, 2014 

J.P. Morgan Securities LLC 
 Goldman, Sachs & Co. 

      As Representatives of the several Initial Purchasers 

      listed in Schedule 1 hereto 

Ladies and Gentlemen: 
 Lexicon Pharmaceuticals,
Inc. a Delaware corporation (the “Company”), proposes to issue and sell to the several initial purchasers listed in Schedule 1 hereto (the “Initial Purchasers”), for whom you are acting as representative (the
“Representatives”), $80,000,000 principal amount of its 5.25% Convertible Notes due 2021 (the “Underwritten Securities”) and, at the option of the Initial Purchasers, up to an additional $15,000,000 principal amount
of its 5.25% Convertible Notes due 2021 (the “Option Securities”) if and to the extent that the Initial Purchasers shall have determined to exercise the option to purchase such 5.25% Convertible Notes due 2021 granted to the Initial
Purchasers in Section 2 hereof. The Underwritten Securities and the Option Securities are herein referred to as the “Securities”. The Securities will be convertible into shares (the “Underlying Securities”) of
common stock of the Company, par value $0.001 per share (the “Common Stock”). The Securities will be issued pursuant to an Indenture to be dated as of November 26, 2014 (the “Indenture”), between the Company
and Wells Fargo Bank, N.A., as trustee (the “Trustee”). 
 The Company hereby confirms its agreement with the several
Initial Purchasers concerning the purchase and sale of the Securities, as follows: 
 1. The Securities will be sold to the Initial
Purchasers without being registered under the Securities Act of 1933, as amended (the “Securities Act”), in reliance upon an exemption therefrom. The Company has prepared a preliminary offering memorandum dated November 19,
2014 (the “Preliminary Offering Memorandum”) and will prepare an offering memorandum dated the date hereof (the “Offering Memorandum”) setting forth information concerning the Company and the Securities. Copies of
the Preliminary Offering Memorandum have been, and copies of the Offering Memorandum will be, delivered by the Company to the Initial Purchasers pursuant to the terms of this purchase agreement (this “Agreement”). The Company hereby
confirms that it has authorized the use of the Preliminary Offering Memorandum, the other Time of Sale Information (as defined below) and the Offering Memorandum in connection 

  
 2 

 
with the offering and resale of the Securities by the Initial Purchasers in the manner contemplated by this Agreement. References herein to the Preliminary Offering Memorandum, the Time of Sale
Information and the Offering Memorandum shall be deemed to refer to and include any document incorporated by reference therein and any reference to “amend,” “amendment” or “supplement” with respect to the Preliminary
Offering Memorandum and the Offering Memorandum shall be deemed to refer to and include any documents filed after such date and incorporated by reference therein. 

At or prior to the time when sales of the Securities were first made (the “Time of Sale”), the Company had prepared the
following information (collectively, the “Time of Sale Information”): the Preliminary Offering Memorandum, as supplemented and amended by the written communications listed on Annex A hereto. 

2. Purchase and Resale of the Securities by the Initial Purchasers. (a) The Company agrees to issue and sell the Underwritten
Securities to the several Initial Purchasers as provided in this Agreement, and each Initial Purchaser, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, agrees, severally
and not jointly, to purchase from the Company the respective principal amount of Underwritten Securities set forth opposite such Initial Purchaser’s name in Schedule 1 hereto at a price equal to 96.5% of the principal amount thereof (the
“Purchase Price”) plus accrued interest, if any, from November 26, 2014 to the Closing Date (as defined below). 
 In
addition, the Company agrees to issue and sell the Option Securities to the several Initial Purchasers as provided in this Agreement, and the Initial Purchasers, on the basis of the representations, warranties and agreements set forth herein and
subject to the conditions set forth herein, shall have the option to purchase, severally and not jointly, from the Company the Option Securities at the Purchase Price plus accrued interest, if any, from November 26, 2014 to the date of payment
and delivery. 
 If any Option Securities are to be purchased, the principal amount of Option Securities to be purchased by each Initial
Purchaser shall be the principal amount of Option Securities which bears the same ratio to the aggregate principal amount of Option Securities being purchased as the principal amount of Underwritten Securities set forth opposite the name of such
Initial Purchaser in Schedule 1 hereto (or such amount increased as set forth in Section 10 hereof) bears to the aggregate principal amount of Underwritten Securities being purchased from the Company by the several Initial Purchasers, subject,
however, to such adjustments to eliminate Securities in denominations other than $1,000 as the Representatives in their sole discretion shall make. 

  
 3 

 The Initial Purchasers may exercise the option to purchase the Option Securities at any time in
whole, or from time to time in part, only for the purpose of covering over-allotments, on or before the thirtieth day following the date of this Agreement, by written notice from the Representatives to the Company. Such notice shall set forth the
aggregate principal amount of Option Securities plus accrued interest as to which the option is being exercised and the date and time when the Option Securities are to be delivered and paid for, which may be the same date and time as the Closing
Date (as hereinafter defined) but shall not be earlier than the Closing Date nor later than the tenth full business day (as hereinafter defined) after the date of such notice (unless such time and date are postponed in accordance with the provisions
of Section 10 hereof). Any such notice shall be given at least two business days prior to the date and time of delivery specified therein. 

(b) The Company understands that the Initial Purchasers intend to offer the Securities for resale on the terms set forth in the Time of Sale
Information. Each Initial Purchaser, severally and not jointly, represents, warrants and agrees that: 
 (i) it is a
qualified institutional buyer (a “QIB”) within the meaning of Rule 144A under the Securities Act (“Rule 144A”) and an accredited investor within the meaning of Rule 501(a) of Regulation D under the Securities Act
(“Regulation D”); 
 (ii) it has not solicited offers for, or offered or sold, and will not solicit offers
for, or offer or sell, the Securities by means of any form of general solicitation or general advertising within the meaning of Rule 502(c) of Regulation D or in any manner involving a public offering within the meaning of Section 4(a)(2) of
the Securities Act; and 
 (iii) it has not solicited offers for, or offered or sold, and will not solicit offers for, or
offer or sell, the Securities as part of their initial offering except within the United States to persons whom it reasonably believes to be QIBs in transactions pursuant to Rule 144A and in connection with each such sale, it has taken or will take
reasonable steps to ensure that the purchaser of the Securities is aware that such sale is being made in reliance on Rule 144A. 
 (c) Each
Initial Purchaser acknowledges and agrees that the Company and, for purposes of the opinions to be delivered to the Initial Purchasers pursuant to Sections 6(c), 6(f) and 6(g), counsel for the Company and counsel for the Initial Purchasers,
respectively, may rely upon the accuracy of the representations and warranties of the Initial Purchasers, and compliance by the Initial Purchasers with their agreements, contained in paragraph (b) above and each Initial Purchaser hereby
consents to such reliance. 

  
 4 

 (d) The Company acknowledges and agrees that the Initial Purchasers may offer and sell Securities
to or through any affiliate of an Initial Purchaser and that any such affiliate may offer and sell Securities purchased by it to or through any Initial Purchaser. 

(e) Payment for the Securities shall be made by wire transfer in immediately available funds to the account specified by the Company to the
Representatives in the case of the Underwritten Securities, at the offices of Ropes & Gray LLP, 800 Boylston Street, Prudential Tower, Boston, Massachusetts 02199 at 10:00 A.M. New York City time on November 26, 2014, or at such other
time or place on the same or such other date, not later than the fifth business day thereafter, as the Representatives and the Company may agree upon in writing or, in the case of the Option Securities, on the date and at the time and place
specified by the Representatives in the written notice of the Initial Purchasers’ election to purchase such Option Securities. The time and date of such payment for the Underwritten Securities is referred to herein as the “Closing
Date” and the time and date for such payment for the Option Securities, if other than the Closing Date, is herein referred to as the “Additional Closing Date”. 

Payment for the Securities to be purchased on the Closing Date or the Additional Closing Date, as the case may be, shall be made against
delivery to the nominee of DTC, for the respective accounts of the several Initial Purchasers of the Securities to be purchased on such date of one or more global notes representing the Securities (collectively, the “Global Note”),
with any transfer taxes payable in connection with the sale of such Securities duly paid by the Company. The Global Note will be made available for inspection by the Representative at the office of J.P. Morgan Securities LLC set forth above not
later than 1:00 P.M., New York City time, on the business day prior to the Closing Date or the Additional Closing Date, as the case may be. 

(f) The Company acknowledges and agrees that each Initial Purchaser is acting solely in the capacity of an arm’s length contractual
counterparty to the Company with respect to the offering of Securities contemplated hereby (including in connection with determining the terms of the offering) and not as a financial advisor or a fiduciary to, or an agent of, the Company or any
other person. Additionally, neither the Representatives nor any other Initial Purchaser is advising the Company or any other person as to any legal, tax, investment, accounting or regulatory matters in any jurisdiction. The Company shall consult
with its own advisors concerning such matters and shall be responsible for making its own independent investigation and appraisal of the transactions contemplated hereby, and neither the Representatives nor any other Initial Purchaser shall have any
responsibility or liability to the Company with respect thereto. Any review by the Representatives or any Initial Purchaser of the Company, the transactions contemplated hereby or other matters relating to such transactions will be performed solely
for the benefit of the Representatives or such Initial Purchaser and shall not be on behalf of the Company or any other person. 

  
 5 

 3. Representations and Warranties of the Company. The Company represents and warrants to
each Initial Purchaser that: 
 (a) The Preliminary Offering Memorandum, as of its date, did not contain any untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided that the Company makes no representation and warranty with respect
to any statements or omissions made in reliance upon and in conformity with information relating to any Initial Purchaser furnished to the Company in writing by such Initial Purchaser through the Representatives expressly for use in any Preliminary
Offering Memorandum. 
 (b) The Time of Sale Information, at the Time of Sale, did not, and at the Closing Date and as of the Additional
Closing Date, as the case may be, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not
misleading; provided that the Company makes no representation and warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Initial Purchaser furnished to the Company in
writing by such Initial Purchaser through the Representatives expressly for use in such Time of Sale Information. No statement of material fact included in the Offering Memorandum has been omitted from the Time of Sale Information and no statement
of material fact included in the Time of Sale Information that is required to be included in the Offering Memorandum in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, has been
omitted therefrom. 
 (c) Other than the Preliminary Offering Memorandum and the Offering Memorandum, the Company (including its agents and
representatives, other than the Initial Purchasers in their capacity as such) has not made, used, prepared, authorized, approved or referred to and will not prepare, make, use, authorize, approve or refer to any “written communication” (as
defined in Rule 405 under the Securities Act) that constitutes an offer to sell or solicitation of an offer to buy the Securities (each such communication by the Company or its agents and representatives (other than a communication referred to in
clauses (i), (ii) and (iii) below) an “Issuer Written Communication”) other than (i) the Preliminary Offering Memorandum, (ii) the Offering Memorandum, (iii) the documents listed on Annex A hereto, including
a term sheet substantially in the form of Annex B hereto, which constitute part of the Time of Sale Information, and (iv) each electronic road show and any other written communications approved in writing in advance by the Representatives. Each
such Issuer Written Communication does not conflict with the information contained in the Time of Sale Information, and when taken together with the Time of Sale Information, did not, and at the Closing Date and as of the Additional Closing Date, as
the case 

  
 6 

 
may be, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading; provided that the Company makes no representation and warranty with respect to any statements or omissions made in each such Issuer Written Communication in reliance upon and in conformity with information
relating to any Initial Purchaser furnished to the Company in writing by such Initial Purchaser through the Representatives expressly for use in such Issuer Written Communication. 

(d) As of the date of the Offering Memorandum and as of the Closing Date and as of the Additional Closing Date, as the case may be, the
Offering Memorandum does not and will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not
misleading; provided that the Company makes no representation and warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Initial Purchaser furnished to the Company in
writing by such Initial Purchaser through the Representatives expressly for use in the Offering Memorandum. 
 (e) The documents incorporated
by reference in the Offering Memorandum or the Time of Sale Information, when filed with the Securities and Exchange Commission (the “Commission”) conformed or will conform, as the case may be, in all material respects to the
requirements of the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission thereunder (collectively, the “Exchange Act”) and such documents did not and will not contain any untrue statement of a
material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. 

(f) The financial statements and the related notes thereto of the Company and its consolidated subsidiaries included or incorporated by
reference in the Time of Sale Information and the Offering Memorandum present fairly in all material respects the financial position of the Company and its consolidated subsidiaries as of the dates indicated and the results of their operations and
the changes in their cash flows for the periods specified; except as otherwise set forth therein, such financial statements have been prepared in conformity with U.S. generally accepted accounting principles applied on a consistent basis throughout
the periods covered thereby; and the other financial information included or incorporated by reference in the Time of Sale Information and the Offering Memorandum has been derived from the accounting records of the Company and its consolidated
subsidiaries and presents fairly in all material respects the information shown thereby. 

  
 7 

 (g) The Company has been duly incorporated, is validly existing as a corporation in good standing
under the laws of the jurisdiction of its incorporation, has the corporate power and authority to own its property and to conduct its business as described in the Time of Sale Information and the Offering Memorandum and is duly qualified to transact
business and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not
have a material adverse effect on the condition, financial or otherwise, or in the earnings, business or operations of the Company and its subsidiaries, taken as a whole (a “Material Adverse Effect”). 

(h) Each subsidiary of the Company has been duly incorporated, is validly existing as a corporation in good standing under the laws of the
jurisdiction of its incorporation, has the corporate power and authority to own its property and to conduct its business as described in the Time of Sale Information and the Offering Memorandum and is duly qualified to transact business and is in
good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not have a Material
Adverse Effect; all of the issued shares of capital stock of each subsidiary of the Company have been duly and validly authorized and issued, are fully paid and non-assessable and are owned directly by the Company, free and clear of all liens,
encumbrances, equities or claims. 
 (i) The authorized capital stock of the Company is as set forth in, and conforms as to legal matters to
the description thereof contained in, each of the Time of Sale Information and the Offering Memorandum. 
 (j) The shares of Common Stock
outstanding prior to the issuance of the Securities have been duly authorized and are validly issued, fully paid and non-assessable. 

(k) There has not occurred any material adverse change, or any development involving a prospective material adverse change, in the condition,
financial or otherwise, or in the earnings, business or operations of the Company and its subsidiaries, taken as a whole, from that set forth in the Time of Sale Information and the Offering Memorandum. 

(l) The Company has full right, power and authority to execute and deliver this Agreement, the Indenture, the Securities, a purchase agreement
dated as of the date hereof between Invus, L.P. or one of its affiliates and the Company (the “Invus Purchase Agreement”) and the indenture related to the securities offered pursuant thereto (collectively, the “Transaction
Documents”) and to perform its obligations hereunder and thereunder; and all action required to be taken for the due and proper authorization, execution and delivery by it of each of the Transaction Documents and the consummation by it of
the transactions contemplated thereby or by the Time of Sale Information and the Offering Memorandum has been duly and validly taken. 

  
 8 

 (m) The Indenture has been duly authorized by the Company and, when duly executed and delivered
in accordance with its terms by each of the parties thereto, will constitute a valid and legally binding agreement of the Company enforceable against the Company in accordance with its terms, except as enforceability may be limited by applicable
bankruptcy, insolvency or similar laws affecting creditors’ rights generally or by equitable principles relating to enforceability (collectively, the “Enforceability Exceptions”); and on the Closing Date, the Indenture will
conform in all material respects to the requirements of the Trust Indenture Act of 1939, as amended (the “Trust Indenture Act”), and the rules and regulations of the Commission applicable to an indenture that is qualified
thereunder. 
 (n) This Agreement has been duly authorized, executed and delivered by the Company. 

(o) The Securities have been duly authorized by the Company and, when duly executed, authenticated, issued and delivered as provided in the
Indenture and paid for as provided herein, will be duly and validly issued and outstanding and will constitute valid and legally binding obligations of the Company enforceable against the Company in accordance with their terms, subject to the
Enforceability Exceptions, and will be entitled to the benefits of the Indenture. 
 (p) Upon issuance and delivery of the Securities in
accordance with this Agreement and the Indenture, the Securities will be convertible at the option of the holder thereof into shares of the Underlying Securities in accordance the terms of the Securities; the maximum number of Underlying Securities
issuable upon conversion of the Securities, including pursuant to any make-whole adjustment, have been duly authorized and reserved for issuance and, when issued upon conversion of the Securities in accordance with the terms of the Securities, will
be validly issued, fully paid and non assessable, and, except as described in the Time of Sale Information and the Offering Memorandum, the issuance of the Underlying Securities will not be subject to any preemptive or similar rights. Except as
described therein, all of such rights described in the Time of Sale Information and the Offering Memorandum have been waived with respect to the issuance of the Securities and the transactions contemplated hereunder, including the maximum number of
Underlying Securities issuable upon conversion of the Securities. 
 (q) Each Transaction Document conforms in all material respects to the
description thereof contained in the Time of Sale Information and the Offering Memorandum. 
 (r) The execution, delivery and performance by
the Company of each of the Transaction Documents, the issuance and sale of the Securities (including the issuance of the Underlying Securities upon conversion thereof) and the consummation of the transactions contemplated by the Transaction
Documents or the Time of Sale Information and the Offering Memorandum will not (i) conflict 

  
 9 

 
with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, or result in the creation or imposition of any lien, charge or encumbrance upon any
property or assets of the Company or any of its subsidiaries pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or
any of its subsidiaries is bound or to which any of the property or assets of the Company or any of its subsidiaries is subject, (ii) result in any violation of the provisions of the charter or by-laws or similar organizational documents of the
Company or any of its subsidiaries or (iii) result in the violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority. 

(s) No consent, approval, authorization, order, license, registration or qualification of or with any court or arbitrator or governmental or
regulatory authority is required for the execution, delivery and performance by the Company of each of the Transaction Documents, the issuance and sale of the Securities (including the issuance of the Underlying Securities upon conversion thereof)
and the consummation of the transactions contemplated by the Transaction Documents or the Time of Sale Information and the Offering Memorandum, except for such consents, approvals, authorizations, orders and registrations or qualifications as may be
required under applicable state securities laws in connection with the purchase and resale of the Securities by the Initial Purchasers. 

(t) The Invus Purchase Agreement has been duly authorized, executed and delivered by the Company and constitutes a valid and legally binding
agreement of the Company enforceable against the Company in accordance with its terms, subject to the Enforceability Exceptions. 
 (u)
Neither the Company nor any of its subsidiaries is a party to any contract, agreement or understanding with any person (other than this Agreement) that would give rise to a valid claim against the Company or any of its subsidiaries or any Initial
Purchaser for a brokerage commission, finder’s fee or like payment in connection with the offering and sale of the Securities. 
 (v) On
the Closing Date and the Additional Closing Date, as the case may be, the Securities will not be of the same class as securities listed on a national securities exchange registered under Section 6 of the Exchange Act or quoted in an automated
inter-dealer quotation system; and each of the Time of Sale Information, as of the Time of Sale, and the Offering Memorandum, as of its date, contains or will contain all the information that, if requested by a prospective purchaser of the
Securities, would be required to be provided to such prospective purchaser pursuant to Rule 144A(d)(4) under the Securities Act. 
 (w)
Except as described in the Time of Sale Information and the Offering Memorandum, there are no contracts, agreements or understandings between the Company and any person granting such person the right to require the Company to file a registration
statement under the Securities Act with respect to any securities of the Company. 

  
 10 

 (x) Neither the Company nor any of its affiliates (as defined in Rule 501(b) of Regulation D)
has, directly or through any agent, sold, offered for sale, solicited offers to buy or otherwise negotiated in respect of, any security (as defined in the Securities Act), that is or will be integrated with the sale of the Securities in a manner
that would require registration of the Securities under the Securities Act. 
 (y) None of the Company or any of its affiliates or any other
person acting on its or their behalf (other than the Initial Purchasers, as to which no representation is made) has (i) solicited offers for, or offered or sold, the Securities by means of any form of general solicitation or general advertising
within the meaning of Rule 502(c) of Regulation D or in any manner involving a public offering within the meaning of Section 4(a)(2) of the Securities Act or (ii) engaged in any directed selling efforts within the meaning of Regulation S
under the Securities Act (“Regulation S”), and all such persons have complied with the offering restrictions requirement of Regulation S. 

(z) Assuming the accuracy of the representations and warranties of the Initial Purchasers contained in Section 2(b) and their compliance
with their agreements set forth therein, it is not necessary, in connection with the issuance and sale of the Securities to the Initial Purchasers and the offer, resale and delivery of the Securities by the Initial Purchasers in the manner
contemplated by this Agreement, the Time of Sale Information and the Offering Memorandum, to register the Securities under the Securities Act or to qualify the Indenture under the Trust Indenture Act. 

(aa) There are no legal or governmental proceedings pending or, to the knowledge of the Company, threatened to which the Company or any of its
subsidiaries is a party or to which any of the properties of the Company or any of its subsidiaries is subject other than proceedings accurately described in all material respects in the Time of Sale Information and the Offering Memorandum and
proceedings that would not reasonably be expected to have a Material Adverse Effect, or on the power or ability of the Company to perform its obligations under this Agreement or to consummate the transactions contemplated by the Time of Sale
Information. 
 (bb) The Company is not, and after giving effect to the offering and sale of the Securities and the application of the
proceeds thereof as described in the Time of Sale Information and the Offering Memorandum will not be, required to register as an “investment company” as such term is defined in the Investment Company Act of 1940, as amended. 

  
 11 

 (cc) The Company and its subsidiaries (i) are in compliance with any and all applicable
foreign, federal, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (“Environmental Laws”),
(ii) have received all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii) are in compliance with all terms and conditions of any such permit, license
or approval, except where such noncompliance with Environmental Laws, failure to receive required permits, licenses or other approvals or failure to comply with the terms and conditions of such permits, licenses or approvals would not, singly or in
the aggregate, have a Material Adverse Effect. 
 (dd) There are no costs or liabilities associated with Environmental Laws (including,
without limitation, any capital or operating expenditures required for clean-up, closure of properties or compliance with Environmental Laws or any permit, license or approval, any related constraints on
operating activities and any potential liabilities to third parties) which would, singly or in the aggregate, have a Material Adverse Effect. 

(ee) The Company has good and marketable title in fee simple to all real property and good and marketable title to all personal property owned
by it which is material to the business of the Company, in each case free and clear of all liens, encumbrances and defects except such as are described in the Time of Sale Information and Offering Memorandum or such as do not materially affect the
value of such property and do not interfere in any material respect with the use made and currently proposed to be made of such property by the Company; and any real property and buildings held under lease by the Company or of its subsidiaries are
held by them under valid, subsisting and enforceable leases with such exceptions as are not material and do not interfere in any material respect with the use made and currently proposed to be made of such property and buildings by the Company, in
each case except as described in the Time of Sale Information and Offering Memorandum. 
 (ff) Except as described in the Time of Sale
Information and Offering Memorandum, (i) the Company and its subsidiaries own, possess, or have valid, binding and enforceable licenses or other rights to use the patents, patent rights and patent applications, copyrights, trademarks, service
marks, trade names, Internet domain names, technology, confidential information, software, know-how, (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures) and other
intellectual property and proprietary rights necessary or used in connection with the conduct of their business in the manner in which it is presently being conducted and in the manner set forth in the Time of Sale Information and the Offering
Memorandum (collectively, the “Company Intellectual Property”), except as would not reasonably be expected to result in a Material Adverse Effect, and to the extent that the Company Intellectual Property is not sufficient to so
conduct their business, including with respect to any products described in the Time of Sale Information and Offering Memorandum as being under development, the Company believes it can acquire such rights on reasonable terms; (ii) to the
knowledge of the Company, (A) none of the patents and patent  

  
 12 

 
applications set forth on Appendix A (collectively, the “Company Patents”) owned by the Company or its subsidiaries is invalid or unenforceable and neither the Company nor any of
its subsidiaries has received any challenge (including without limitation, notices of expiration) to the validity or enforceability of Company Patents from any third party or governmental authority and the Company and its subsidiaries have made all
filings and paid all fees necessary to maintain any Company Patents owned by any of them, and (B) none of the Company Intellectual Property owned by the Company or its subsidiaries is invalid or unenforceable and neither the Company nor any of
its subsidiaries has received any challenge (including without limitation, notices of expiration) to the validity or enforceability of Company Intellectual Property from any third party or governmental authority and the Company and its subsidiaries
have made all filings and paid all fees necessary to maintain any Company Intellectual Property owned by any of them, except as would not reasonably be expected to result in a Material Adverse Effect for Company Intellectual Property other than
Company Patents; (iii) the Company and its subsidiaries have taken reasonable measures necessary to secure their interests in Company Intellectual Property, including the confidentiality of all trade secrets and confidential information which
constitutes Company Intellectual Property, and to secure assignment of Company Intellectual Property from its employees and contractors; (iv) the Company is not aware of any Company Intellectual Property required to be described in the Time of
Sale Information and the Offering Memorandum; (v) neither the Company nor any of its subsidiaries has received any claim of infringement or misappropriation of (and the Company does not know of any infringement or misappropriation of)
intellectual property rights of others by the Company or any of its subsidiaries (A) with respect to the Company Patents or (B) with respect to the Company Intellectual Property, except as would not reasonably be expected to result in a
Material Adverse Effect for Company Intellectual Property other than Company Patents; (vi) the Company and its subsidiaries are not in breach of, and have complied with all terms of, any license or other agreement relating to any Company
Intellectual Property, and no party to any such agreement has given the Company or its subsidiaries notice of its intention to cancel, terminate, alter the scope of rights under or fail to renew any such agreement, except as would not reasonably be
expected to result in a Material Adverse Effect; and (vii) no suit or other proceeding is pending against the Company or any of its subsidiaries concerning any agreement concerning the Company Intellectual Property, including any proceeding
concerning a claim that the Company or its subsidiaries or another person has breached any such agreement. 
 (gg) All patent
applications owned by the Company and filed with the U.S. Patent Trademark Office (“PTO”) or any foreign or international patent authority (the “Company Patent Applications”) have been duly and properly filed; the
Company has complied with its duty of candor and disclosure to the PTO for the Company Patent Applications; the Company is not aware of any facts required to be disclosed to the PTO that were not disclosed to the PTO and which would preclude the
grant of a patent for the Company Patent Applications; and the Company has no knowledge of any facts which would preclude it from having clear title to the Company Patent Applications that have been identified by the Company as being exclusively
owned by the Company. 

  
 13 

 (hh) No material labor dispute with the employees of the Company exists, except as described in
the Time of Sale Information and the Offering Memorandum, or, to the knowledge of the Company, is imminent; and the Company is not aware of any existing, threatened or imminent labor disturbance by the employees of any of its principal suppliers,
manufacturers or contractors that could have a Material Adverse Effect. 
 (ii) The Company is insured by insurers of recognized financial
responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which it is engaged. The Company has no reason to believe that it will not be able to renew its existing insurance coverage as and
when such coverage expires or obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not have a Material Adverse Effect, except as described in the Time of Sale Information and Offering
Memorandum. 
 (jj) The Company possesses all certificates, authorizations and permits issued by the appropriate federal, state or foreign
regulatory authorities necessary to conduct its business as presently conducted and in the manner set forth in the Time of Sale Information and Offering Memorandum, including without limitation all such certificates, authorizations and permits
required by the United States Food and Drug Administration (the “FDA”) or any other federal, state or foreign agencies or bodies engaged in the regulation of pharmaceuticals or biohazardous materials, except as would not reasonably
be expected to result in a Material Adverse Effect, and the Company has not received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit which, singly or in the aggregate, if the
subject of an unfavorable decision, ruling or finding, would have a Material Adverse Effect, except as described in the Time of Sale Information and the Offering Memorandum. 

(kk) The studies, tests and preclinical and clinical trials conducted by or on behalf of the Company that are described in the Time of Sale
Information and Offering Memorandum were and, if still pending, are, to the Company’s knowledge, being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to, where applicable, accepted
professional and scientific standards for products or product candidates comparable to those being developed by the Company; the descriptions of the results of such studies, tests and trials contained in the Time of Sale Information and Offering
Memorandum do not contain any misstatement of a material fact or omit to state a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Time of Sale
Information and the Offering Memorandum the results of which reasonably call into question in any material respect the results of the studies, tests 

  
 14 

 
and trials described in the Time of Sale Information or the Offering Memorandum; and the Company has not received any notices or correspondence from the FDA or any foreign, state or local
governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on
behalf of the Company which termination, suspension or material modification would reasonably be expected to have a Material Adverse Effect. 

(ll) Except as described in the Time of Sale Information and the Offering Memorandum, the Company and its subsidiaries are in compliance with,
and conduct their respective businesses in conformity with, all applicable federal, state and local laws and regulations, except where the failure to so comply or conform would not reasonably be expected to have a Material Adverse Effect. 

(mm) Ernst & Young LLP, who have certified certain financial statements of the Company and its subsidiaries, are independent public
accountants as required by the Securities Act and the rules and regulations of the Commission thereunder. 
 (nn) The Company maintains a
system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions are recorded as necessary to
permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s general or specific
authorization; and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Except as described in the Time of Sale Information,
since the end of the Company’s most recent audited fiscal year, there has been (i) no material weakness in the Company’s internal control over financial reporting (whether or not remediated) and (ii) no change in the
Company’s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting. The interactive data in eXtensible Business Reporting
Language included or incorporated by reference in the Time of Sale Information and the Offering Memorandum fairly presents the information called for in all material respects and has been prepared in accordance with the Commission’s rules and
guidelines applicable thereto in all material respects. 
 (oo) Except as described in the Time of Sale Information and Offering Memorandum,
the Company has not sold, issued or distributed any shares of Common Stock during the six-month period preceding the date hereof, including any sales pursuant to Rule 144A under, or Regulation D or S of, the Securities Act, other than shares issued
pursuant to employee benefit plans, qualified stock option plans or other employee compensation plans or pursuant to outstanding options, rights or warrants. 

  
 15 

 (pp) Each material contract, agreement and license to which the Company is bound is valid,
binding, enforceable, and in full force and effect against the Company, and to the knowledge of the Company, each other party thereto, subject to the Enforceability Exceptions. Neither the Company nor, to the Company’s knowledge, any other
party is in breach or default in any material respect with respect to any such contract, agreement and license, and, to the Company’s knowledge, no event has occurred which with notice or lapse of time would constitute a material breach or
default, or permit termination, modification, or acceleration, under any such contract, agreement or license. To the knowledge of the Company, no party has repudiated any material provision of any such contract, agreement or license. 

(qq) Neither the Company nor any of its subsidiaries, nor, to the knowledge of the Company, any director, officer or employee of the Company or
any of its subsidiaries nor any agent, affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries has (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful
expense relating to political activity; (ii) made or taken an act in furtherance of an offer, promise or authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic government official or employee, including
of any government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political
office; (iii) violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in
International Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom or any other applicable anti-bribery or anti-corruption law; or (iv) made, offered, agreed, requested or taken an act in furtherance
of any unlawful bribe or other unlawful benefit, including, without limitation, any rebate, payoff, influence payment, kickback or other unlawful or improper payment or benefit. 

(rr) The operations of the Company and its subsidiaries are and have been conducted at all times in material compliance with applicable
financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the applicable money laundering statutes of all jurisdictions where the Company or any of its
subsidiaries conducts business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or enforced by any governmental agency (collectively, the “Anti-Money Laundering
Laws”) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to
the knowledge of the Company, threatened. 

  
 16 

 (ss) Neither the Company nor any of its subsidiaries, nor, to the knowledge of the Company, any
directors, officers, or employees of the Company, nor any agent, affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries is currently the subject or the target of any sanctions administered or enforced
by the U.S. government, (including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury (“OFAC”) or the U.S. Department of State and including, without limitation, the designation as a
“specially designated national” or “blocked person”), the United Nations Security Council (“UNSC”), the European Union, Her Majesty’s Treasury (“HMT”) or other relevant sanctions authority
(collectively, “Sanctions”), nor is the Company, any of its subsidiaries located, organized or resident in a country or territory that is the subject or target of Sanctions, including, without limitation, Cuba, Iran, North Korea,
Sudan and Syria (each, a “Sanctioned Country”); and the Company will not directly or indirectly use the proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise make available such proceeds to any
subsidiary, joint venture partner or other person or entity (i) to fund or facilitate any activities of or business with any person that, at the time of such funding or facilitation, is the subject or target of Sanctions, (ii) to fund or
facilitate any activities of or business in any Sanctioned Country or (iii) in any other manner that will result in a violation by any person (including any person participating in the transaction, whether as underwriter, advisor, investor or
otherwise) of Sanctions. 
 (tt) There is and has been no failure on the part of the Company or any of the Company’s directors or
officers, in their capacities as such, to comply in all material respects with any provision of the Sarbanes-Oxley Act of 2002, as amended and the rules and regulations promulgated in connection therewith (the “Sarbanes-Oxley Act”),
including Section 402 related to loans and Sections 302 and 906 related to certifications, that is applicable to the Company. 

4. Further Agreements of the Company. The Company covenants and agrees with each Initial Purchaser that: 

(a) Delivery of Copies. The Company will deliver to the Initial Purchasers as many copies of the Preliminary Offering Memorandum, any
other Time of Sale Information, any Issuer Written Communication and the Offering Memorandum (including all amendments and supplements thereto) as the Representatives may reasonably request. 

(b) Offering Memorandum, Amendments or Supplements. Before finalizing the Offering Memorandum or making or distributing any amendment or
supplement to any of the Time of Sale Information or the Offering Memorandum or filing with the Commission any document that will be incorporated by reference therein, the Company will furnish to the Representatives and counsel for the Initial
Purchasers a copy of the proposed Offering Memorandum or such amendment or supplement or document to be incorporated by reference therein for review, and will not distribute any such proposed Offering Memorandum, amendment or supplement or file any
such document with the Commission to which the Representatives reasonably objects. 

  
 17 

 (c) Additional Written Communications. Before making, preparing, using, authorizing,
approving or referring to any Issuer Written Communication, the Company will furnish to the Representatives and counsel for the Initial Purchasers a copy of such written communication for review and will not make, prepare, use, authorize, approve or
refer to any such written communication to which the Representatives reasonably objects. 
 (d) Notice to the Representatives. The
Company will advise the Representatives promptly, and confirm such advice in writing, (i) of the issuance by any governmental or regulatory authority of any order preventing or suspending the use of any of the Time of Sale Information, any
Issuer Written Communication or the Offering Memorandum or the initiation or threatening of any proceeding for that purpose; (ii) of the occurrence or development of any event at any time prior to the completion of the initial offering of the
Securities as a result of which any of the Time of Sale Information, any Issuer Written Communication or the Offering Memorandum as then amended or supplemented would include any untrue statement of a material fact or omit to state a material fact
necessary in order to make the statements therein, in the light of the circumstances existing when such Time of Sale Information, Issuer Written Communication or the Offering Memorandum is delivered to a purchaser, not misleading; and (iii) of
the receipt by the Company of any notice with respect to any suspension of the qualification of the Securities for offer and sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and the Company will use its
reasonable best efforts to prevent the issuance of any such order preventing or suspending the use of any of the Time of Sale Information, any Issuer Written Communication or the Offering Memorandum or suspending any such qualification of the
Securities and, if any such order is issued, will obtain as soon as possible the withdrawal thereof. 
 (e) Ongoing Compliance of the
Offering Memorandum and Time of Sale Information. (1) If at any time prior to the completion of the initial offering of the Securities (i) any event or development shall occur or condition shall exist as a result of which the Offering
Memorandum as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Offering
Memorandum is delivered to a purchaser, not misleading or (ii) it is necessary to amend or supplement the Offering Memorandum to comply with law, the Company will immediately notify the Initial Purchasers thereof and forthwith prepare and,
subject to paragraph (b) above, furnish to the Initial Purchasers such amendments or supplements to the Offering Memorandum (or any document to be filed with the Commission and incorporated by reference therein) as may be necessary so that the
statements in the Offering Memorandum as so amended or supplemented (or including such 

  
 18 

 
document to be incorporated by reference therein) will not, in the light of the circumstances existing when the Offering Memorandum is delivered to a purchaser, be misleading or so that the
Offering Memorandum will comply with law and (2) if at any time prior to the Closing Date (i) any event or development shall occur or condition shall exist as a result of which any of the Time of Sale Information as then amended or
supplemented would include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading or (ii) it is
necessary to amend or supplement any of the Time of Sale Information to comply with law, the Company will immediately notify the Initial Purchasers thereof and forthwith prepare and, subject to paragraph (b) above, furnish to the Initial
Purchasers such amendments or supplements to any of the Time of Sale Information (or any document to be filed with the Commission and incorporated by reference therein) as may be necessary so that the statements in any of the Time of Sale
Information as so amended or supplemented will not, in light of the circumstances under which they were made, be misleading. 
 (f) Blue
Sky Compliance. The Company will qualify the Securities for offer and sale under the securities or blue sky laws of such jurisdictions as the Representatives shall reasonably request and will continue such qualifications in effect so long as
required for the offering and resale of the Securities. 
 (g) Clear Market. The Company also covenants with each Initial Purchaser
that, without the prior written consent of each of the Representatives, it will not, during the restricted period set forth in Schedule I hereto, (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any
option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common
Stock or (2) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction described in clause (1) or (2) above
is to be settled by delivery of Common Stock or such other securities, in cash or otherwise or (3) file any registration statement with the Commission relating to the offering of any shares of Common Stock or any securities convertible into or
exercisable or exchangeable for Common Stock. The foregoing sentence shall not apply to (a) the Securities to be sold hereunder, securities to be sold pursuant to the Invus Purchase Agreement or shares of Common Stock to be sold pursuant to a
concurrent public offering, (b) the issuance by the Company of shares of Common Stock upon the exercise of an option or warrant, the vesting of a restricted stock unit or the conversion of a security outstanding on the date hereof of which the
Initial Purchasers have been advised in writing, (c) the grant by the Company of restricted stock awards, restricted stock units or options to purchase shares of Common Stock under the Company’s Equity Incentive Plan as in effect on the
date hereof or the 

  
 19 

 
Company’s Non-Employee Directors’ Equity Incentive Plan as in effect on the date hereof, (d) the issuance by the Company of shares of Common Stock to Symphony Icon Holdings LLC
(“Holdings”) or its designee or designees in partial satisfaction of its contingent payment obligations under the Amended and Restated Purchase Option Agreement, dated July 30, 2010, between the Company, Holdings and Symphony
Icon, Inc. triggered by the Company’s receipt of an upfront payment of $23 million under the License and Collaboration Agreement, dated October 21, 2014, between the Company and Ipsen Pharma SAS, and the filing of a registration statement
(or amendment thereto) with the Commission relating to the resale of such shares of Common Stock, or (e) the establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act for the transfer of shares of Common Stock, provided
that such plan does not provide for the transfer of Common Stock during the 90-day restricted period, except as otherwise permitted herein, and no public announcement or filing under the Exchange Act regarding
the establishment of such plan shall be required of or voluntarily made by or on behalf of the Company. Notwithstanding the foregoing, if (1) during the last 17 days of the 90-day restricted period the Company issues an earnings release or
material news or a material event relating to the Company occurs; or (2) prior to the expiration of the 90-day restricted period, the Company announces that it will release earnings results during the 16-day period beginning on the last day of the 90-day period, the restrictions imposed by this agreement shall continue to apply until the expiration of the 18-day period beginning on the issuance of the earnings release or the occurrence of the material news or material event. The Company shall promptly notify the Representatives of any earnings release, news or event
that may give rise to an extension of the initial 90-day restricted period. 
 (i) Use of Proceeds. The Company will apply the net
proceeds from the sale of the Securities as described in the Time of Sale Information and the Offering Memorandum under the heading “Use of Proceeds”. 

(j) No Stabilization. The Company will not take, directly or indirectly, any action designed to or that could reasonably be expected to
cause or result in any stabilization or manipulation of the price of the Securities and will not take any action prohibited by Regulation M under the Exchange Act in connection with the distribution of the Securities contemplated hereby. 

(k) Underlying Securities. The Company will reserve and keep available at all times, free of pre-emptive rights, shares of Common Stock
for the purpose of enabling the Company to satisfy all obligations to issue the Underlying Securities upon conversion of the Securities. The Company will use its best efforts to cause the Underlying Securities to be listed on the Nasdaq Global
Select Market (the “Exchange”). 
 (l) Supplying Information. While the Securities remain outstanding and are
“restricted securities” within the meaning of Rule 144(a)(3) under the 

  
 20 

 
Securities Act, the Company will, during any period in which the Company is not subject to and in compliance with Section 13 or 15(d) of the Exchange Act, furnish to holders of the
Securities, prospective purchasers of the Securities designated by such holders and securities analysts, in each case upon request, the information required to be delivered pursuant to Rule 144A(d)(4) under the Securities Act. 

(m) DTC. The Company will assist the Initial Purchasers in arranging for the Securities to be eligible for clearance and settlement
through DTC. 
 (o) No Resales by the Company. During the period from the Closing Date until one year after the Closing Date or the
Additional Closing Date, if applicable, the Company will not, and will not permit any of its affiliates (as defined in Rule 144 under the Securities Act) to resell any of the Securities that have been acquired by any of them, except for Securities
purchased by the Company or any of its affiliates and resold in a transaction registered under the Securities Act. 
 (p) No
Integration. Neither the Company nor any of its affiliates (as defined in Rule 501(b) of Regulation D) will, directly or through any agent, sell, offer for sale, solicit offers to buy or otherwise negotiate in respect of, any security (as
defined in the Securities Act), that is or will be integrated with the sale of the Securities in a manner that would require registration of the Securities under the Securities Act. 

(q) No General Solicitation or Directed Selling Efforts. None of the Company or any of its affiliates or any other person acting on its
or their behalf (other than the Initial Purchasers, as to which no covenant is given) will (i) solicit offers for, or offer or sell, the Securities by means of any form of general solicitation or general advertising within the meaning of Rule
502(c) of Regulation D or in any manner involving a public offering within the meaning of Section 4(a)(2) of the Securities Act or (ii) engage in any directed selling efforts within the meaning of Regulation S, and all such persons will
comply with the offering restrictions requirement of Regulation S. 
 5. Certain Agreements of the Initial Purchasers. Each Initial
Purchaser hereby represents and agrees that it has not and will not use, authorize use of, refer to, or participate in the planning for use of, any written communication that constitutes an offer to sell or the solicitation of an offer to buy the
Securities other than (i) the Preliminary Offering Memorandum and the Offering Memorandum, (ii) a written communication that contains no “issuer information” (as defined in Rule 433(h)(2) under the Securities Act) that was not
included (including through incorporation by reference) in the Preliminary Offering Memorandum or the Offering Memorandum, (iii) any written communication listed on Annex A or prepared pursuant to Section 4(c) above (including any
electronic road show), (iv) any written communication prepared by 

  
 21 

 
such Initial Purchaser and approved by the Company in advance in writing or (v) any written communication relating to or that contains the terms of the Securities and/or other information
that was included (including through incorporation by reference) in the Preliminary Offering Memorandum or the Offering Memorandum. 
 6.
Conditions of Initial Purchasers’ Obligations. The obligation of each Initial Purchaser to purchase the Underwritten Securities on the Closing Date or the Option Securities on the Additional Closing Date, as the case may be as
provided herein is subject to the performance by the Company of its covenants and other obligations hereunder and to the following additional conditions: 

(a) Subsequent to the execution and delivery of this Agreement and prior to the Closing Date or the Additional Closing Date, as the case may
be, there shall not have occurred any change, or any development involving a prospective change, in the condition, financial or otherwise, or in the earnings, business or operations of the Company and its subsidiaries, taken as a whole, from that
set forth in the Time of Sale Information (excluding any amendment or supplement thereto) and the Offering Memorandum (excluding any amendment or supplement thereto) as of the date of this Agreement that, in your judgment, is material and adverse
and that makes it, in your judgment, impracticable to market the Securities on the terms and in the manner contemplated in this Agreement, the Time of Sale Information and the Offering Memorandum. 

(b) The Initial Purchasers s shall have received on the Closing Date or the Additional Closing Date, as the case may be, a certificate, dated
the Closing Date or the Additional Closing Date, as applicable, and signed by an executive officer of the Company, to the effect that the representations and warranties of the Company contained in this Agreement are true and correct as of the
Closing Date or the Additional Closing Date, as applicable, and that the Company has complied with all of the agreements and satisfied all of the conditions on its part to be performed or satisfied hereunder on or before the Closing Date or the
Additional Closing Date, as applicable. The officer signing and delivering such certificate may rely upon the best of his or her knowledge as to proceedings threatened. 

(c) The Initial Purchasers shall have received on the Closing Date or the Additional Closing Date, as the case may be, an opinion of
Vinson & Elkins, L.L.P., outside counsel for the Company, dated the Closing Date or the Additional Closing Date, as applicable, in form and substance acceptable to the Initial Purchasers, to the effect set forth in Annex C hereto. 

(d) The Initial Purchasers shall have received on the Closing Date or the Additional Closing Date, as the case may be, an opinion of Brian T.
Crum, Vice President and General Counsel of the Company, dated the Closing Date or the Additional Closing Date, as applicable, in form and substance acceptable to the Initial Purchasers. 

  
 22 

 (e) The Initial Purchasers shall have received on the Closing Date or the Additional Closing
Date, as the case may be, an opinion of Max Bachrach, Ph.D., Vice President, Intellectual Property, of the Company, dated the Closing Date or the Additional Closing Date, as applicable, in form and substance acceptable to the Initial Purchasers.

 (f) The Initial Purchasers shall have received on the Closing Date or the Additional Closing Date, as the case may be, an opinion of
Ropes & Gray LLP, counsel for the Initial Purchasers, dated the Closing Date or the Additional Closing Date, as applicable, in form and substance acceptable to the Initial Purchasers. 

(g) The Initial Purchasers shall have received on the Closing Date or the Additional Closing Date, as the case may be, an opinion of Davis
Polk & Wardwell LLP, counsel for the Initial Purchasers, dated the Closing Date or the Additional Closing Date, as applicable, in form and substance acceptable to the Initial Purchasers. 

(h) The Initial Purchasers shall have received, on each of the date hereof and the Closing Date or the Additional Closing Date, as the
case may be, a letter dated the date hereof or the Closing Date or the Additional Closing Date, as the case may be, in form and substance satisfactory to the Initial Purchasers, from Ernst & Young LLP, independent public accountants,
containing statements and information of the type ordinarily included in accountants’ “comfort letters” to the initial purchasers with respect to the financial statements and certain financial information contained in, or incorporated
by reference into, the Time of Sale Information and the Offering Memorandum; provided that the letter delivered on the Closing Date shall use a “cut-off date” not earlier than the date
hereof. 
 (i) The Initial Purchasers shall have received, on each of the date hereof and the Closing Date or the Additional Closing
Date, as the case may be, a certificate of the chief financial officer of the Company, dated the date hereof or the Closing Date or the Additional Closing Date, as the case may be, in form and substance satisfactory to the Initial Purchasers. 

(j) The Securities shall be eligible for clearance and settlement through DTC. 

(k) The “lock-up” agreements, each substantially in the form of Exhibit A hereto, between you and certain shareholders, officers and
directors of the Company relating to sales and certain other dispositions of shares of Common Stock or certain other securities, delivered to you on or before the date hereof, shall be full force and effect on the Closing Date or Additional Closing
Date, as the case may be. 

  
 23 

 (l) Substantially concurrently with the delivery of the Underwritten Securities, the issuance and
sale of the Shares (as that term is defined in that certain purchase agreement, dated as of November 20, 2014, between the Company, Invus, L.P., Invus C.V. and Artal International S.C.A. (the “Purchase Agreement”)) shall be
consummated pursuant to the terms and conditions of the Purchase Agreement. 
 The several obligations of the Initial Purchasers to purchase
Option Securities hereunder are subject to the delivery to you on the applicable Additional Closing Date of such documents as you may reasonably request with respect to the good standing of the Company, the due authorization and issuance of the
Option Securities to be sold on such Additional Closing Date and other matters related to the issuance of such Option Securities. 
 7.
Indemnification and Contribution. 
 (a) Indemnification of the Initial Purchasers. The Company agrees to indemnify and hold
harmless each Initial Purchaser, its affiliates, directors, officers, agents and employees and each person, if any, who controls such Initial Purchaser within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange
Act, from and against any and all losses, claims, damages and liabilities (including, without limitation, any legal or other expenses reasonably incurred in connection with defending or investigating any such action or claim) caused by any untrue
statement or alleged untrue statement of a material fact contained in the Preliminary Offering Memorandum, any of the other Time of Sale Information, any Issuer Written Communication, any road show as defined in Rule 433(h) under the Securities Act
(a “road show”) or the Offering Memorandum (or any amendment or supplement thereto) or any omission or alleged omission to state therein a material fact necessary in order to make the statements therein, in light of the circumstances under
which they were made, not misleading, in each case except insofar as such losses, claims, damages or liabilities are caused by any such untrue statement or omission based upon information relating to any Initial Purchaser furnished to the Company in
writing by such Initial Purchaser through the Representatives expressly for use therein. 
 (b) Indemnification of the Company. Each
Initial Purchaser agrees, severally and not jointly, to indemnify and hold harmless the Company, its directors, its officers and each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or
Section 20 of the Exchange Act to the same extent as the indemnity set forth in paragraph (a) above, but only with reference to information relating to such Initial Purchaser furnished to the Company in writing by such Initial Purchaser
through the Representatives expressly for use in the Preliminary Offering Memorandum, any of the other Time of Sale Information, any Issuer Written Communication, any road show or the Offering Memorandum (or any amendment or supplement thereto).

  
 24 

 (c) Notice and Procedures. If any suit, action or proceeding (including any governmental
or regulatory investigation) shall be brought or asserted against any person in respect of which indemnification may be sought pursuant to either paragraph (a) or (b) above, such person (the “Indemnified Person”) shall
promptly notify the person against whom such indemnification may be sought (the “Indemnifying Person”) in writing; provided that the failure to notify the Indemnifying Person shall not relieve it from any liability that it
may have under paragraph (a) or (b) above except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure and the Indemnifying Person shall retain counsel reasonably
satisfactory to the Indemnified Person to represent the Indemnified Person and any others the Indemnifying Person may designate in such proceeding and shall pay the fees and disbursements of such counsel related to such proceeding. In any such
proceeding, any Indemnified Person shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such Indemnified Person unless (i) the Indemnifying Person and the Indemnified Person shall
have mutually agreed to the contrary or (ii) the named parties in any such proceeding (including any impleaded parties include both the Indemnifying Person and the Indemnified Person and representation of both parties by the same counsel would
be inappropriate due to actual or potential differing interest between them. It is understood and agreed that the Indemnifying Person shall not, in connection with any proceeding or related proceeding in the same jurisdiction, be liable for the fees
and expenses of more than one separate firm (in addition to any local counsel) for all Indemnified Persons, and that all such fees and expenses shall be reimbursed as they are incurred. Any such separate firm for any Initial Purchaser, its
affiliates, directors and officers and any control persons of such Initial Purchaser shall be designated in writing by J.P. Morgan Securities LLC and any such separate firm for the Company, its directors, its officers and any control persons of the
Company shall be designated in writing by the Company. The Indemnifying Person shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the
plaintiff, the Indemnifying Person agrees to indemnify each Indemnified Person from and against any loss or liability by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an Indemnified Person shall have
requested that an Indemnifying Person reimburse the Indemnified Person for fees and expenses of counsel as contemplated by this paragraph, the Indemnifying Person shall be liable for any settlement of any proceeding effected without its written
consent if (i) such settlement is entered into more than 30 days after receipt by the Indemnifying Person of such request and (ii) the Indemnifying Person shall not have reimbursed the Indemnified Person in accordance with such request
prior to the date of such settlement. No Indemnifying Person shall, without the written consent of the Indemnified Person, effect any settlement of any pending or threatened proceeding in respect of which any Indemnified Person is or could have been
a party and indemnification could have been sought hereunder by such Indemnified Person, unless such settlement includes an unconditional release of such Indemnified Person, in form and substance reasonably satisfactory to such Indemnified Person,
from all liability on claims that are the subject matter of such proceeding. 

  
 25 

 (d) Contribution. If the indemnification provided for in paragraphs (a) or
(b) above is unavailable to an Indemnified Person or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each Indemnifying Person under such paragraph, in lieu of indemnifying such Indemnified Person
thereunder, shall contribute to the amount paid or payable by such Indemnified Person as a result of such losses, claims, damages or liabilities (i) in such proportion as is appropriate to reflect the relative benefits received by the Company,
on the one hand, and the Initial Purchasers, on the other, from the offering of the Securities or (ii) if the allocation provided by clause (i) is not permitted by applicable law, in such proportion as is appropriate to reflect not only
the relative benefits referred to in clause (i) but also the relative fault of the Company, on the one hand, and the Initial Purchasers, on the other, in connection with the statements or omissions that resulted in such losses, claims, damages
or liabilities, as well as any other relevant equitable considerations. The relative benefits received by the Company, on the one hand, and the Initial Purchasers, on the other, shall be deemed to be in the same respective proportions as the net
proceeds (before deducting expenses) received by the Company from the sale of the Securities and the total discounts and commissions received by the Initial Purchasers in connection therewith, as provided in this Agreement, bear to the aggregate
offering price of the Securities. The relative fault of the Company, on the one hand, and the Initial Purchasers, on the other, shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material
fact or the omission or alleged omission to state a material fact relates to information supplied by the Company or by the Initial Purchasers and the parties’ relative intent, knowledge, access to information and opportunity to correct or
prevent such statement or omission. 
 (e) Limitation on Liability. The Company and the Initial Purchasers agree that it would not be
just and equitable if contribution pursuant to this Section 7 were determined by pro rata allocation (even if the Initial Purchasers were treated as one entity for such purpose) or by any other method of allocation that does not
take account of the equitable considerations referred to in paragraph (d) above. The amount paid or payable by an Indemnified Person as a result of the losses, claims, damages and liabilities referred to in paragraph (d) above shall be
deemed to include, subject to the limitations set forth above, any legal or other expenses reasonably incurred by such Indemnified Person in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this
Section 7, in no event shall an Initial Purchaser be required to contribute any amount in excess of the amount by which the total price at which the Securities purchased by it and distributed were reoffered exceeds the amount of any damages
that such Initial Purchaser has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the
Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Initial Purchasers’ obligations to contribute pursuant to this Section 7 are several in proportion to their
respective purchase obligations hereunder and not joint. 

  
 26 

 (f) Non-Exclusive Remedies. The remedies provided for in this Section 7 are not
exclusive and shall not limit any rights or remedies which may otherwise be available to any Indemnified Person at law or in equity. 
 8.
Effectiveness of Agreement. This Agreement shall become effective upon the execution and delivery hereof by the parties hereto. 
 9.
Termination. The Representatives may terminate this Agreement by notice given by you to the Company, if after the execution and delivery of this Agreement and prior to the Closing Date or, in the case of the Option Securities, prior to the
Additional Closing Date (i) trading generally shall have been suspended or materially limited on, or by, as the case may be, either of the New York Stock Exchange or the NASDAQ Global Select Market, (ii) trading of any securities of the
Company shall have been suspended on any exchange or in any over-the-counter market, (iii) a material disruption in securities settlement, payment or clearance
services in the United States shall have occurred, (iv) any moratorium on commercial banking activities shall have been declared by Federal or New York State authorities or (v) there shall have occurred any outbreak or escalation of
hostilities, or any change in financial markets or any calamity or crisis that, in your judgment, is material and adverse and which, singly or together with any other event specified in this clause (v), makes it, in your judgment, impracticable
or inadvisable to proceed with the offer, sale or delivery of the Securities on the terms and in the manner contemplated in this Agreement, the Time of Sale Information and the Offering Memorandum. 

10. Defaulting Initial Purchaser. (a) If, on the Closing Date or the Additional Closing Date, as the case may be, any Initial
Purchaser defaults on its obligation to purchase the Securities that it has agreed to purchase hereunder on such date, the non-defaulting Initial Purchasers may in their discretion arrange for the purchase of such Securities by other persons
satisfactory to the Company on the terms contained in this Agreement. If, within 36 hours after any such default by any Initial Purchaser, the non-defaulting Initial Purchasers do not arrange for the purchase of such Securities, then the Company
shall be entitled to a further period of 36 hours within which to procure other persons satisfactory to the non-defaulting Initial Purchasers to purchase such Securities on such terms. If other persons become obligated or agree to purchase the
Securities of a defaulting Initial Purchaser, either the non-defaulting Initial Purchasers or the Company may postpone the Closing Date or the Additional Closing Date, as the case may be, for up to five full
business days in order to effect any changes that in the opinion of counsel for the Company or counsel for the Initial Purchasers may be necessary in the Time of Sale Information, the Offering Memorandum or in any other document or arrangement, and
the Company agrees to promptly prepare any amendment or supplement to the Time of Sale Information or the Offering Memorandum that 

  
 27 

 
effects any such changes. As used in this Agreement, the term “Initial Purchaser” includes, for all purposes of this Agreement unless the context otherwise requires, any person not
listed in Schedule 1 hereto that, pursuant to this Section 10, purchases Securities that a defaulting Initial Purchaser agreed but failed to purchase. 

(b) If, after giving effect to any arrangements for the purchase of the Securities of a defaulting Initial Purchaser or Initial Purchasers by
the non-defaulting Initial Purchasers and the Company as provided in paragraph (a) above, the aggregate number of Securities that remain unpurchased on the Closing Date or the Additional Closing Date, as the case may be does not exceed
one-eleventh of the aggregate number of Securities to be purchased on such date, then the Company shall have the right to require each non-defaulting Initial Purchaser to purchase the number of Securities that such Initial Purchaser agreed to
purchase hereunder on such date plus such Initial Purchaser’s pro rata share (based on the number of Securities that such Initial Purchaser agreed to purchase on such date) of the Securities of such defaulting Initial Purchaser or Initial
Purchasers for which such arrangements have not been made. 
 (c) If, after giving effect to any arrangements for the purchase of the
Securities of a defaulting Initial Purchaser or Initial Purchasers by the non-defaulting Initial Purchasers and the Company as provided in paragraph (a) above, the aggregate number of Securities that remain unpurchased on the Closing Date or
the Additional Closing Date, as the case may be, exceeds one-eleventh of the aggregate principal amount of Securities to be purchased on such date, or if the Company shall not exercise the right described in paragraph (b) above, then this
Agreement or, with respect to any Additional Closing Date, the obligation of the Initial Purchasers to purchase Securities on the Additional Closing Date, as the case may be, shall terminate without liability on the part of the non-defaulting
Initial Purchasers. Any termination of this Agreement pursuant to this Section 10 shall be without liability on the part of the Company, except that the Company will continue to be liable for the payment of expenses as set forth in
Section 11 hereof and except that the provisions of Section 7 hereof shall not terminate and shall remain in effect. 
 (d) Nothing
contained herein shall relieve a defaulting Initial Purchaser of any liability it may have to the Company or any non-defaulting Initial Purchaser for damages caused by its default. 

11. Payment of Expenses. (a) Whether or not the transactions contemplated by this Agreement are consummated or this Agreement is
terminated, the Company will pay or cause to be paid all costs and expenses incident to the performance of its obligations hereunder, including without limitation, (i) the costs incident to the authorization, issuance, sale, preparation and
delivery of the Securities and any taxes payable in that connection; (ii) the costs incident to the preparation and printing of the Preliminary Offering Memorandum, any other Time of Sale Information, any Issuer Written Communication and the
Offering Memorandum (including any amendments and supplements thereto) and 

  
 28 

 
the distribution thereof; (iii) the costs of reproducing and distributing each of the Transaction Documents; (iv) the fees and expenses of the Company’s counsel and independent
accountants; (v) the fees and expenses incurred in connection with the registration or qualification and determination of eligibility for investment of the Securities under the laws of such jurisdictions as the Representatives may designate and
the preparation, printing and distribution of a blue sky memorandum (including the related fees and expenses of counsel for the Initial Purchasers); (vi) any fees charged by rating agencies for rating the Securities; (vii) the fees and
expenses of the Trustee and any paying agent (including related fees and expenses of any counsel to such parties); (viii) all expenses and application fees incurred in connection with the approval of the Securities for book-entry transfer by
DTC; (ix) all expenses incurred by the Company in connection with any “road show” presentation to potential investors; and (x) all expenses and application fees related to the listing of the Underlying Securities on the Exchange.
It is understood, however, that except as provided in this Section and Section 7 entitled “Indemnity and Contribution,” and Section 10(b), the Initial Purchasers will pay all of their costs and expenses, including fees and
disbursements of their counsel, transfer taxes payable on resale of any of the Securities by them and any advertising expenses connected with any offers they may make. 

(b) If this Agreement shall be terminated by the Initial Purchasers, or any of them, because of any failure or refusal on the part of the
Company to comply with the terms or to fulfill any of the conditions of this Agreement, or if for any reason the Company shall be unable to perform its obligations under this Agreement, the Company will reimburse the Underwriters or such
Underwriters as have so terminated this Agreement with respect to themselves, severally, for all out of pocket expenses (including the fees and disbursements of their counsel) reasonably incurred by such Underwriters in connection with this
Agreement or the offering contemplated hereunder. 
 12. Persons Entitled to Benefit of Agreement. This Agreement shall inure to the
benefit of and be binding upon the parties hereto and their respective successors and the officers and directors and any controlling persons referred to in Section 7 hereof. Nothing in this Agreement is intended or shall be construed to give
any other person any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein. No purchaser of Securities from any Initial Purchaser shall be deemed to be a successor merely by reason of such
purchase. 
 13. Survival. The respective indemnities, rights of contribution, representations, warranties and agreements of the
Company and the Initial Purchasers contained in this Agreement or made by or on behalf of the Company or the Initial Purchasers pursuant to this Agreement or any certificate delivered pursuant hereto shall survive the delivery of and payment for the
Securities and shall remain in full force and effect, regardless of any termination of this Agreement or any investigation made by or on behalf of the Company or the Initial Purchasers. 

  
 29 

 14. Certain Defined Terms. For purposes of this Agreement, (a) except where otherwise
expressly provided, the term “affiliate” has the meaning set forth in Rule 405 under the Securities Act; and (b) the term “business day” means any day other than a day on which banks are permitted or required to be closed in
New York City. 
 15. Compliance with USA Patriot Act. In accordance with the requirements of the USA Patriot Act (Title III of Pub.
L. 107-56 (signed into law October 26, 2001)), the Initial Purchasers are required to obtain, verify and record information that identifies their respective clients, including the Company, which information may include the name and address of
their respective clients, as well as other information that will allow the Initial Purchasers to properly identify their respective clients. 

16. Miscellaneous. (a) Notices. All notices and other communications hereunder shall be in writing and shall be deemed to
have been duly given if mailed or transmitted and confirmed by any standard form of telecommunication. Notices to the Initial Purchasers shall be given to the Representatives c/o J.P. Morgan Securities LLC, 383 Madison Avenue, New York, New York
10179 (fax: (212) 622-8358); Attention: Equity Syndicate Desk and c/o Goldman, Sachs & Co., 200 West Street, New York, New York 10282-2198, Attention: Registration Department, with a copy to Ropes & Gray LLP, Prudential Tower,
800 Boylston Street, Boston, MA 02199, Attention: Patrick O’Brien. Notices to the Company shall be given to it at Lexicon Pharmaceuticals, Inc., 8800 Technology Forest Place, The Woodlands, TX 77381, Attention: Brian Crum. 

(b) Governing Law. This Agreement and any claim, controversy or dispute arising under or related to this Agreement shall be governed by
and construed in accordance with the laws of the State of New York. 
 (f) Counterparts. This Agreement may be signed in counterparts
(which may include counterparts delivered by any standard form of telecommunication), each of which shall be an original and all of which together shall constitute one and the same instrument. 

(g) Amendments or Waivers. No amendment or waiver of any provision of this Agreement, nor any consent or approval to any departure
therefrom, shall in any event be effective unless the same shall be in writing and signed by the parties hereto. 
 (h) Headings. The
headings herein are included for convenience of reference only and are not intended to be part of, or to affect the meaning or interpretation of, this Agreement. 

  
 30 

 (i) Xtract Research LLC. The Company hereby agrees that the Initial Purchasers may provide
copies of the Preliminary Offering Memorandum and the Offering Memorandum relating to the offering of the Securities and any other agreements or documents relating thereto, including, without limitation, trust indentures, to Xtract Research LLC
(“Xtract”) following the completion of the offering for inclusion in an online research service sponsored by Xtract, access to which is restricted to “qualified institutional buyers” as defined in Rule 144A under the
Securities Act. 

  
 31 

 If the foregoing is in accordance with your understanding, please indicate your acceptance of
this Agreement by signing in the space provided below. 
  

			
	Very truly yours,
	
	Lexicon Pharmaceuticals, Inc.
		
	By	 	 /s/ Lonnel Coats

		 	Name: Lonnel Coats
		 	Title: President & CEO

  

	
	Accepted: As of the date first written above
	
	J.P. Morgan Securities LLC
	Goldman, Sachs & Co.
	
	 For itself and on behalf of the

several Initial Purchasers listed

in Schedule 1 hereto.

  

			
	By:	 	J.P. Morgan Securities LLC
		
	By:	 	   /s/ Yun Xie

		 	Name: Yun Xie
		 	Title: Vice President
		
	By:	 	Goldman, Sachs & Co.
		
	By:	 	   /s/ Daniel Young

		 	Name: Daniel Young
		 	Title: Managing Director

  
 32 

 Schedule 1 
  

													
	 Initial Purchaser
	  	Principal
Amount of
Underwritten
Securities	 	  	Principal
Amount of
Option Securities	 	  	Total
Principal
Amount of
Securities	 
	 J.P. Morgan Securities LLC
	  	$	44,000,000.00	  	  	$	8,250,000.00	  	  	$	52,250,000.00	  
	 Goldman, Sachs & Co.
	  	 	36,000,000.00	  	  	 	6,750,000.00	  	  	 	42,750,000.00	  
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
	 Total:
	  	$	80,000,000.00	  	  	$	15,000,000.00	  	  	$	95,000,000.00	  
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 

  
 33 

 Annex A 

a. Time of Sale Information 
 Term sheet
containing the terms of the Securities, substantially in the form of Annex B. 

  
 34 

 Annex B 
  

			
	PRICING TERM SHEET	  	STRICTLY CONFIDENTIAL
	Dated November 20, 2014	  	

 Lexicon Pharmaceuticals, Inc. 

$80,000,000 
 5.25%
Convertible Senior Notes due 2021 
 The information in this pricing term sheet supplements Lexicon Pharmaceuticals, Inc.’s preliminary offering
memorandum, dated November 19, 2014 (the “Preliminary Offering Memorandum”), and supersedes the information in the Preliminary Offering Memorandum to the extent inconsistent with the information in the Preliminary Offering Memorandum.
In all other respects, this term sheet is qualified in its entirety by reference to the Preliminary Offering Memorandum. Terms used herein but not defined herein shall have the respective meanings as set forth in the Preliminary Offering Memorandum.
All references to dollar amounts are references to U.S. dollars. References to “we,” “us,” “our,” “Lexicon,” “Lexicon Pharmaceuticals,” the “Company” and similar designations refer to
Lexicon Pharmaceuticals, Inc. and not to its consolidated subsidiaries. 
  

			
	Issuer:	  	Lexicon Pharmaceuticals, Inc., a Delaware corporation
		
	Title of securities:	  	5.25% Convertible Senior Notes due 2021 (the “Notes”)
		
	Ticker / Exchange:	  	LXRX / The Nasdaq Global Select Market (“Nasdaq”)
		
	Aggregate principal amount offered:	  	$80,000,000 aggregate principal amount of Notes
		
	Over-allotment option:	  	Up to an additional $15,000,000 aggregate principal amount of Notes
		
	Offering price:	  	The Notes will be issued at a price of 100% of their principal amount, plus accrued interest, if any, from the settlement date
		
	Maturity:	  	December 1, 2021, unless earlier repurchased or converted
		
	Interest rate:	  	5.25% per annum, accruing from the settlement date
		
	Interest payment dates:	  	Each June 1 and December 1, beginning on June 1, 2015
		
	Last reported sale price of the Issuer’s common stock on November 20, 2014:	  	$1.005 per share of the Issuer’s common stock
		
	Initial conversion rate:	  	829.1874 shares of the Issuer’s common stock for each $1,000 principal amount of Notes
		
	Initial conversion price:	  	$1.206 per share of the Issuer’s common stock
		
	Conversion premium:	  	20% above the last reported sale price of the Issuer’s common stock on November 20, 2014
		
	Trade date:	  	November 20, 2014
		
	Expected settlement date:	  	November 26, 2014
		
	Joint book-running managers:	  	J.P. Morgan Securities LLC Goldman, Sachs & Co.

			
	CUSIP (144A):	  	528872 AA2
		
	ISIN (144A):	  	US528872AA29
		
	Use of proceeds:	  	 The Issuer estimates that the proceeds from the offering of Notes after deducting the estimated offering expenses and the initial
purchasers’ discount will be approximately $77.0 million (or $91.5 million if the initial purchasers exercise their over-allotment option in full).
  

The Issuer currently intends to use the net proceeds from the offering of Notes, together with the net proceeds from the Common Stock Offering and the Private
Placement, as defined below, for the clinical development of its drug candidates and its other nonclinical research and development efforts. The Issuer may also use a portion of the net proceeds to acquire or invest in complementary products and
technologies or for general corporate purposes.

		
	Common stock offering:	  	Concurrently with the offering of Notes, the Issuer is offering up to 49,751,244 shares of its common stock (or a total of up to 57,213,931 shares of its common stock if the underwriters in that offering exercise in full their
option to purchase additional shares of common stock), in a registered underwritten offering pursuant to a prospectus supplement (the “Common Stock Offering”) at a public offering price of $1.005 per share, for total gross proceeds of $50
million ($57.5 million if the underwriters in that offering exercise in full their option to purchase additional shares of common stock).
		
	Private placement:	  	Concurrently with the offering of Notes and the Common Stock Offering, the Issuer will enter into a stock purchase agreement with Invus L.P., Invus C.V. (together with Invus L.P., “Invus”) and Artal International S.C.A.
(“Artal”) pursuant to which Artal will agree to purchase and the Issuer will agree to issue to Artal on the closing date of the Common Stock Offering an aggregate of 149,253,731 shares of the Issuer’s common stock at a price of $1.005
per share, equal to the price per share to the public in the Common Stock Offering (the “Private Placement”), for total gross proceeds of $150 million.
		
	Common stock to be outstanding after the Common Stock Offering and the Private Placement:	  	 713,839,502 shares (or 721,302,189 shares if the underwriters in the Common Stock Offering exercise in full their option to purchase
additional shares of common stock), excluding the shares underlying the Notes.
  
 After
the Common Stock Offering and the Private Placement, Invus and its affiliates will hold approximately 60.58% of the outstanding shares of the Issuer’s common stock (or 59.95% if the underwriters in that offering exercise in full their option to
purchase additional shares of common stock).

  
 2 

			
		
	Payment to Symphony:	  	The $23 million upfront payment the Issuer received from Ipsen Pharma SAS triggers the Issuer’s obligation to pay Symphony Icon Holdings LLC approximately $11.5 million in December 2014. The Issuer has the option of paying up
to 50% of this payment to Symphony in shares of the Issuer’s common stock. Although the Issuer has not made a determination of whether to issue shares in respect of the payment, the terms of the purchase agreement for this offering permit the
Issuer to do so and to file a registration statement with the Securities and Exchange Commission for the resale of these shares prior to the issuance of such shares.
		
	Repurchase of Notes at the holders’ option upon a fundamental change:	  	Holders may require the Issuer to repurchase their Notes for cash upon the occurrence of a “fundamental change” (as defined under “Description of notes—Fundamental change permits holders to require us to
repurchase notes” in the Preliminary Offering Memorandum) at a price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the “fundamental change repurchase
date” (as defined under “Description of notes—Fundamental change permits holders to require us to repurchase notes” in the Preliminary Offering Memorandum).
		
	Adjustment to shares delivered upon conversion upon a make-whole adjustment event:	  	The following table sets forth the number of “additional shares” (as defined under “Description of notes—Conversion rights—Increase in conversion rate upon conversion upon a make-whole fundamental
change” in the Preliminary Offering Memorandum) by which the conversion rate will be increased per $1,000 principal amount of Notes for each stock price and effective date set forth below:

  

																																																	
	 	  	Stock Price	 
	 Effective Date
	  	$1.005	 	  	$1.05	 	  	$1.10	 	  	$1.15	 	  	$1.20	 	  	$1.40	 	  	$1.60	 	  	$1.75	 	  	$2.00	 	  	$2.25	 	  	$2.50	 	  	$3.00	 
	 November 26, 2014
	  	 	165.8374	  	  	 	163.2116	  	  	 	148.6581	  	  	 	135.3804	  	  	 	124.8559	  	  	 	88.0562	  	  	 	64.6545	  	  	 	51.7920	  	  	 	36.2121	  	  	 	25.5313	  	  	 	18.0758	  	  	 	6.4713	  
	 December 1, 2015
	  	 	165.8374	  	  	 	162.4288	  	  	 	147.7753	  	  	 	134.7196	  	  	 	123.0068	  	  	 	87.5155	  	  	 	63.8213	  	  	 	50.9423	  	  	 	35.4896	  	  	 	24.9930	  	  	 	17.7086	  	  	 	6.3516	  
	 December 1, 2016
	  	 	165.8374	  	  	 	161.5050	  	  	 	146.8781	  	  	 	133.2578	  	  	 	121.1693	  	  	 	84.9255	  	  	 	61.2501	  	  	 	48.5823	  	  	 	33.5906	  	  	 	23.5468	  	  	 	16.6486	  	  	 	5.8299	  
	 December 1, 2017
	  	 	165.8374	  	  	 	160.0764	  	  	 	146.2881	  	  	 	131.7169	  	  	 	118.9526	  	  	 	81.3233	  	  	 	57.5463	  	  	 	45.1457	  	  	 	30.8071	  	  	 	21.4246	  	  	 	15.0930	  	  	 	5.0609	  
	 December 1, 2018
	  	 	165.8374	  	  	 	158.8107	  	  	 	141.7162	  	  	 	126.0230	  	  	 	112.5943	  	  	 	73.8697	  	  	 	50.6707	  	  	 	39.0720	  	  	 	26.1706	  	  	 	18.0499	  	  	 	12.7162	  	  	 	3.9636	  
	 December 1, 2019
	  	 	165.8374	  	  	 	153.5993	  	  	 	133.2344	  	  	 	115.9500	  	  	 	101.3618	  	  	 	61.3876	  	  	 	39.5826	  	  	 	29.5715	  	  	 	19.2951	  	  	 	13.3099	  	  	 	9.5510	  	  	 	2.6503	  
	 December 1, 2020
	  	 	165.8374	  	  	 	139.5507	  	  	 	115.3626	  	  	 	95.0648	  	  	 	78.7834	  	  	 	37.9547	  	  	 	20.5288	  	  	 	14.3823	  	  	 	9.5616	  	  	 	7.3393	  	  	 	5.9874	  	  	 	1.5856	  
	 December 1, 2021
	  	 	165.8374	  	  	 	121.2183	  	  	 	78.0335	  	  	 	40.4135	  	  	 	0.0000	  	  	 	0.0000	  	  	 	0.0000	  	  	 	0.0000	  	  	 	0.0000	  	  	 	0.0000	  	  	 	0.0000	  	  	 	0.0000	  

 The exact stock prices and effective dates may not be set forth in the table above, in which case: 

 

	 	•	 	if the stock price is between two stock prices in the table or the effective date is between two effective dates in the table, the number of additional shares by which the conversion rate will be increased will be
determined by a straight-line interpolation between the number of additional shares set forth for the higher and lower stock prices and the earlier and later effective dates, as applicable, based on a 365-day year.; 

 

	 	•	 	if the stock price is greater than $3.00 per share (subject to adjustment in the same manner as the stock prices set forth in the column headings of the table above), no additional shares will be added to the conversion
rate; and 

  

	 	•	 	if the stock price is less than $1.005 per share (subject to adjustment in the same manner as the stock prices set forth in the column headings of the table above), no additional shares will be added to the conversion
rate. 

 Notwithstanding the foregoing, in no event will the conversion rate per $1,000 principal amount of Notes exceed 995.0248 shares of
common stock, subject to adjustment in the same manner as the conversion rate as set forth under “Description of notes—Conversion rate adjustments” in the Preliminary Offering Memorandum. 

[Remainder of Page Intentionally Blank] 

  
 3 

 This communication is confidential and is intended for the sole use of the person to whom it is provided by
the sender. This information does not purport to be a complete description of the Notes or the offering. 
 This communication does not constitute an
offer to sell or the solicitation of an offer to buy any Notes in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. 

The offer and sale of the Notes and the common stock issuable upon conversion thereof have not been registered, and will not be registered, under the
Securities Act of 1933, as amended (the “Securities Act”), or any other securities laws, and the Notes and such common stock may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons except
pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws. Accordingly, the Notes are being offered and sold only to “qualified institutional
buyers” (as defined in Rule 144A under the Securities Act). 
 The Notes and any shares of common stock issuable upon conversion of the Notes
are not transferable except in accordance with the restrictions described under “Notice to investors” and “Transfer restrictions” in the Preliminary Offering Memorandum. 

A copy of the Preliminary Offering Memorandum for the offering of the Notes may be obtained by contacting (i) J.P. Morgan Securities LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone at (866) 803-9204 or (ii) Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at
(212) 902-1171, or by emailing prospectus-ny@ny.email.gs.com. 
 Any legends, disclaimers or other notices that may appear below are not
applicable to this communication and should be disregarded. Such legends, disclaimers or other notices have been automatically generated as a result of this communication having been sent via Bloomberg or another system. 

  
 4 

 Annex C 

Form of Opinion of Counsel for the Company 

(i) the Company has been duly incorporated, is validly existing as a corporation in good standing under the laws of the jurisdiction of its
incorporation, has the corporate power and authority to own its property and to conduct its business as described in the Time of Sale Information and is duly qualified to transact business and is in good standing in each jurisdiction as set forth in
an Annex to such counsel’s opinion; 
 (ii) each Subsidiary of the Company has been duly incorporated or formed, as the case may be, and
is validly existing as a corporation, limited liability company or limited partnership, as the case may be, in good standing under the laws of the jurisdiction of its incorporation or formation, has the corporate, limited liability company or
limited partnership, as the case may be, power and authority to own its property and to conduct its business as described in the Time of Sale Prospectus and is duly qualified to transact business and is in good standing in each jurisdiction as set
forth in an Annex to such counsel’s opinion; 
 (iii) the authorized capital stock of the Company conforms as to legal matters to the
description thereof contained in each of the Time of Sale Information and the Offering Memorandum; 
 (iv) all of the issued shares of
capital stock or other equity interests of each Subsidiary of the Company (A) have been duly and validly authorized and issued, (B) are fully paid and non-assessable (except as such nonassessability may be affected by Sections 17-607 and
17-804 of the Delaware LP Act and Sections 18-607 and 18-804 of the Delaware LLC Act, as applicable) and (C) are owned directly or indirectly by the Company, (D) free and clear of all liens, encumbrances, equities or claims in respect
of which a financing statement under the Uniform Commercial Code of the State of Delaware naming the Company as debtor is on file in the office of the Secretary of State of the State of Delaware or the Uniform Commercial Code of the State of Texas
naming the Company as debtor is on file in the office of the Secretary of State of the State of Texas or of which we otherwise have actual knowledge; 

(v) This Agreement has been duly authorized, executed and delivered by the Company; 

(vi) The Indenture has been duly authorized, executed and delivered by the Company and, assuming due execution and delivery thereof by the
Trustee, constitutes a valid and legally binding agreement of the Company enforceable against the Company in accordance with its terms; 

(vii) The Securities are in the form contemplated by the Indenture, have been duly authorized, executed and delivered by the Company and, when
duly authenticated as provided in the Indenture and paid for as provided in this Agreement, will be duly and validly issued and outstanding and will constitute valid and legally binding obligations of the Company enforceable against the Company in
accordance with their terms, and will be entitled to the benefits of the Indenture; 

  
 5 

 (viii) the Underlying Shares issuable upon conversion of the Securities (including any Securities
issuable upon conversion in connection with a “make-whole fundamental change”) have been duly authorized and reserved for issuance and, when issued upon conversion of the Securities in accordance with the terms of the Securities, will be
validly issued, fully paid and non-assessable, and the issuance of such Shares will not be subject to any preemptive or similar rights that are contained in the Company’s Restated Certificate of Incorporation and Amended and Restated Bylaws, in
each case as amended to the date hereof, or any agreement filed as an exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, any subsequent quarterly report filed by the Company on Form 10-Q, or any
subsequent report filed by the Company on Form 8-K, other than such as have been satisfied or waived with respect to Invus, L.P. and Invus C.V. under the Stockholders’ Agreement, dated June 17, 2007, by and between the Company and Invus,
L.P., as amended by that Supplement to Transactions Agreements, dated March 15, 2010 and Supplement to Transaction Agreements No. 2, dated February 23, 2012, each by and between the Company, Invus, L.P. and Invus C.V.; 

(ix) The execution, delivery and performance by the Company of the Indenture, this Agreement, the Securities and the compliance by the Company
with the terms thereof, the issuance and sale of the Securities being delivered on the Closing Date or the Additional Closing Date, as the case may be, (including the issuance of the Underlying Securities upon conversion thereof, including any
Securities issuable upon conversion in connection with a “make-whole fundamental change”) and the consummation of the transactions contemplated thereby (i) will not conflict with or result in a breach or violation of any of the terms
or provisions of, or constitute a default under, or result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company or any of its Subsidiaries pursuant to, any indenture, mortgage, deed of trust,
loan agreement or other agreement or instrument identified on Annex B [to include all material contracts filed with the 10-K or subsequent 10-Q or 8-K], (ii) will not result in any violation of the provisions of the charter or by-laws or
similar organizational documents of the Company or any of its Subsidiaries or (iii) will not result in the violation of any federal or New York state statute or the Delaware General Corporation Law, the Delaware Limited Liability Company Act,
the Delaware Revised Uniform Limited Partnership Act, or any rule or regulation thereunder except, in the case of clauses (i) and (iii) above, for such conflict, breach, violation or default that would not, individually or in the
aggregate, have a Material Adverse Effect, except that it is understood that no opinion is given in this paragraph with respect to any federal or state securities law or any rule or regulation issued pursuant to any federal or state securities law;

 (x) No consent, approval, authorization, order, registration, filing or qualification of or with any federal, Texas or New York state
governmental agency or body or any Delaware state governmental agency or body acting pursuant to the Delaware General Corporation Law, the Delaware Limited Liability Company Act or the Delaware Revised Uniform Limited Partnership Act or, to our
knowledge, any federal, Texas or New York state court or any Delaware state court acting pursuant to the Delaware General Corporation Law, the Delaware Limited Liability Company Act or the Delaware Revised Uniform Limited Partnership Act is required
for the issuance and sale of the Securities being delivered on the Closing Date or the Additional Closing Date, as the case may be, (including the issuance of the Underlying Securities upon conversion thereof including any Securities issuable upon
conversion in connection with a “make-whole fundamental change”) and the execution, delivery and compliance by the Company with all of the provisions of this Agreement and the Indenture, except that it is understood that no opinion is
given in this paragraph with respect to any federal or state securities law or any rule or regulation issued pursuant to any federal or state securities law; 

  
 6 

 (xi) the statements in the Time of Sale Information and Offering Memorandum under the headings
“Description of Notes”, “Certain Federal Income Tax Considerations” and “Description of Capital Stock,” to the extent that they constitute summaries of the terms of the Securities or stock, matters of law or regulation
or legal conclusions, are accurate in all material respects; 
 (xii) the Company is not, and after giving effect to the offering and sale of
the Shares and the application of the proceeds thereof as described in the Prospectus will not be, required to register as an “investment company” as such term is defined in the Investment Company Act of 1940, as amended; 

(xiii) Assuming the accuracy of the representations, warranties and agreements of the Company and the Initial Purchasers contained in this
Agreement, it is not necessary, in connection with the issuance and sale of the Securities to the Initial Purchasers and the offer, resale and delivery of the Securities by the Initial Purchasers in the manner contemplated by this Agreement, the
Time of Sale Information and the Offering Memorandum, to register the Securities under the Securities Act or to qualify the Indenture under the Trust Indenture Act; 

(xiv) To our actual knowledge, there are no legal or governmental proceedings pending or threatened to which the Company or any of its
Subsidiaries is a party or to which any of the properties of the Company or any of its Subsidiaries is subject that are required to be described in the Time of Sale Information or Offering Memorandum and are not so described or of any statutes,
regulations, contracts or other documents that are required to be described in the Time of Sale Information or Offering Memorandum or required to be incorporated by reference therein; and 

In addition, such counsel shall state that although the primary purpose of its engagement was not to establish or confirm factual matters or
financial or accounting matters and because of the wholly or partially non-legal character of many of the statements contained in the Time of Sale Information and the Offering Memorandum and the reports filed
by the Company with the Commission pursuant to the Exchange Act and incorporated by reference in the Time of Sale Information and the Offering Memorandum (the “Exchange Act Reports”), and that such counsel is not passing upon and does not
assume any responsibility for the accuracy, completeness or fairness of the statements contained in the Time of Sale Information, the Offering Memorandum and the Exchange Act Reports (except to the extent expressly set forth in paragraphs
(iii) and (xi) above), and such counsel has not independently verified the accuracy, completeness or fairness of such statements (except as aforesaid). Such counsel has, however, participated in conferences with officers and other
representatives of the Company and with representatives of its independent accounts, and legal counsel for, you, at which the contents of the Time of Sale Information and the Offering Memorandum were discussed. Based on such participation and
review, and subject to the limitations described above, such counsel advises you that no facts have come to its attention that cause it to believe that (in each case, excluding the financial statements and the notes thereto and the related schedules
and other information of a financial, accounting or statistical nature included therein or omitted therefrom, as to which such counsel has not been asked to comment); 

(i) the Time of Sale Information, at the Time of Sale (which such counsel may assume to be the date of this Agreement)
contained any untrue statement of a material fact or omitted to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; or 

  
 7 

 (ii) that the Offering Memorandum or any amendment or supplement thereto as of its date and the
Closing Date contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading (other than the financial
statements and other financial information contained therein, as to which such counsel need express no belief). 
 The opinion of
Vinson & Elkins LLP described above shall be rendered to the Initial Purchasers at the request of the Company and shall so state therein. 

  
 8 

 Exhibit A 

FORM OF LOCK-UP AGREEMENT 
 J.P. Morgan
Securities LLC 
 Goldman, Sachs & Co. 
 As Managers of
the 
 several Underwriters listed 
 in Schedule II to the
Underwriting 
 Agreement and Representatives of the 
 several
Initial Purchasers listed 
 in Schedule 1 to the Purchase 

Agreement referred to below 
  

	c/o	J.P. Morgan Securities LLC 

 383 Madison Avenue 

New York, NY 10179 
  

	c/o	Goldman, Sachs & Co. 

 200 West Street 

New York, NY 10282 
 Ladies and Gentlemen: 

The undersigned understands that J.P. Morgan Securities LLC (“J.P. Morgan”) and Goldman, Sachs & Co.
(“Goldman”) propose to enter into an Underwriting Agreement (the “Underwriting Agreement”) with Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “Company”), providing for the public
offering (the “Public Offering”) by the several Underwriters listed in Schedule II to the Underwriting Agreement, including J.P. Morgan and Goldman (the “Underwriters”), of shares (the “Shares”) of
the common stock, par value $0.001 per share, of the Company (the “Common Stock”). The undersigned also understands that J.P. Morgan and Goldman propose to enter into a purchase agreement (the “Purchase Agreement”)
with the Company providing for the purchase and resale (“Placement” and together with the Public Offering, the “Offerings”) by the several initial purchasers named in Schedule 1 to the Purchase Agreement, including
J.P. Morgan and Goldman (the “Initial Purchasers”), of notes convertible into Common Stock of the Company (the “Securities”). 

To induce the Underwriters and Initial Purchasers that may participate in the Offerings to continue their efforts in connection with the
Offerings, the undersigned hereby agrees that, without the prior written consent of J.P. Morgan and Goldman on behalf of the Underwriters and the Initial Purchasers, it will not, during the period commencing on the date hereof and ending 90 days
after the later of the date of the final prospectus supplement relating to the Public Offering (the “Prospectus”) or the date of the final offering memorandum relating to the Placement (the “Offering Memorandum”),
(1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, 

 
lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock beneficially owned (as such term is used in Rule 13d-3 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”)), by the undersigned or any other securities so owned convertible into or exercisable or exchangeable for Common Stock or (2) enter into any swap or other arrangement that transfers to another, in
whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of Common Stock or such other securities, in cash or
otherwise. The foregoing sentence shall not apply to (a) transactions relating to shares of Common Stock or other securities acquired in open market transactions after the completion of the Offerings, provided that no filing under
Section 16(a) of the Exchange Act, shall be required or shall be voluntarily made in connection with subsequent sales of Common Stock or other securities acquired in such open market transactions, (b) any surrender of shares of Common
Stock (or options to purchase shares of Common Stock) to the Company by the undersigned in satisfaction of (i) any federal, state or local taxes required by law to be withheld with respect to the vesting of shares of Common Stock or the
exercise of stock options to purchase Common Stock and/or (ii) the exercise price payable to the Company with respect to the exercise of stock options to purchase Common Stock, in each case granted under a stock incentive plan or stock purchase
plan of the Company described in the Prospectus and the Offering Memorandum or any document incorporated by reference therein and in accordance with the terms of any such instrument as in effect on or before the date hereof, (c) transfers of
shares of Common Stock or any security convertible into Common Stock as a bona fide gift, (d) distributions of shares of Common Stock or any security convertible into Common Stock to limited partners or stockholders of the undersigned,
(e) transfers to immediate family of the undersigned, to a trust all of the beneficiaries of which are the undersigned and/or members of his or her immediate family or to a corporation, partnership, limited partnership or limited liability
company all of the stockholders, partners and members of which are the undersigned and/or members of his or her immediate family, in each case for estate planning purposes; provided that (i) in the case of any transfer or distribution
pursuant to clause (c)—(e) each donee or distributee shall sign and deliver a lock-up letter substantially in the form of this letter and (ii) in the case of any surrender, transfer or
distribution pursuant to clause (b)—(e), no filing under Section 16(a) of the Exchange Act, reporting a reduction in beneficial ownership of shares of Common Stock, shall be required or shall be voluntarily made during the restricted
period referred to in the foregoing sentence, except to reflect the surrender of shares of Common Stock to the Company by the undersigned on February 28, 2015 pursuant to clause (b)(1) above upon the vesting of restricted stock units granted to
the undersigned by the Company on February 23, 2011, February 15, 2012, February 8, 2013 and February 6, 2014 or (f) the establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act for the
transfer of shares of Common Stock, provided that such plan does not provide for the transfer of Common Stock during the restricted period, except as otherwise permitted herein, and no public announcement or filing under the Exchange Act
regarding the establishment of such plan shall be required of or voluntarily made by or on behalf of the undersigned or the Company. For purposes of this agreement, “immediate family” shall mean spouse, lineal descendant, father, mother,
brother or sister of the transferor. 
 In addition, the undersigned agrees that, without the prior written consent of J.P. Morgan and
Goldman on behalf of the Underwriters and Initial Purchasers, it will not, during the period commencing on the date hereof and ending 90 days after the later of the date of the Prospectus or the Offering Memorandum, make any demand for or exercise
any right with respect to, the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock. The undersigned also agrees and consents to the entry of stop transfer instructions with the
Company’s transfer agent and registrar against the transfer of the undersigned’s shares of Common Stock except in compliance with the foregoing restrictions. 

  
 2 

 If: 

(1) during the last 17 days of the restricted period the Company issues an earnings release or material news or a material event relating to
the Company occurs; or 
 (2) prior to the expiration of the restricted period, the Company announces that it will release earnings results
during the 16-day period beginning on the last day of the restricted period; 
 the restrictions imposed by this
agreement shall continue to apply until the expiration of the 18-day period beginning on the issuance of the earnings release or the occurrence of the material news or material event. 

The undersigned shall not engage in any transaction that may be restricted by this agreement during the
34-day period beginning on the last day of the initial restricted period unless the undersigned requests and receives prior written confirmation from the Company or J.P. Morgan and Goldman that the
restrictions imposed by this agreement have expired. 
 The undersigned understands that the Company, the Underwriters and the Initial
Purchasers are relying upon this agreement in proceeding toward consummation of the Offerings. The undersigned further understands that this agreement is irrevocable and shall be binding upon the undersigned’s heirs, legal representatives,
successors and assigns. 
 Notwithstanding the foregoing, this agreement shall terminate and have no further force or effect if the Public
Offering is not consummated by December 1, 2014. 

  
 3 

 Whether or not the Offerings actually occurs depends on a number of factors, including market
conditions. Each Offering will only be made pursuant to an Underwriting Agreement or Purchase Agreement, as the case may be, the terms of which are subject to negotiation between the Company and the Underwriters or Initial Purchasers, as applicable.

  

	
	Very truly yours,
	
	  

	(Name)
	
	  

	(Address)

  
 4 

 Appendix A 

LG103 
  

															
	 Case Reference
	 	 Country
	 	 Filing
	 	 Filing Number
	 	 Publication
	 	 Publication
Number
	 	 Grant
	 	 Grant Number

	 LEX-1002-AT-EPT
	 	Austria	 	12 Dec 2006	 	06849951.6	 	29 Oct 2008	 	1984344	 	26 Sep 2012	 	1984344
	 LEX-1002-AU-PCT
	 	Australia	 	12 Dec 2006	 	2006337137	 		 		 	27 Sep 2012	 	2006337137
	 LEX-1002-BE-EPT
	 	Belgium	 	12 Dec 2006	 	06849951.6	 	29 Oct 2008	 	1984344	 	26 Sep 2012	 	1984344
	 LEX-1002-BR-PCT
	 	Brazil	 	12 Dec 2006	 	PI0620756-1	 	22 Nov 2011	 	2133	 		 	
	 LEX-1002-CA-PCT
	 	Canada	 	12 Dec 2006	 	2,635,531	 		 		 	17 Jun 2014	 	2,635,531
	 LEX-1002-CH-EPT
	 	Switzerland	 	12 Dec 2006	 	06849951.6	 	29 Oct 2008	 	1984344	 	26 Sep 2012	 	1984344
	 LEX-1002-CN-PCD
	 	China	 	20 Feb 2013	 	201310082551.2	 	28 Aug 2013	 	CN 103265495A	 		 	
	 LEX-1002-CN-PCT
	 	China	 	12 Dec 2006	 	200680049907.0	 	21 Jan 2009	 	CN101351451A	 	20 Feb 2013	 	ZL200680049907.0
	 LEX-1002-CO-PCT
	 	Colombia	 	12 Dec 2006	 	08.074.441	 	30 Nov 2009	 	610	 	28 Jun 2012	 	1798
	 LEX-1002-CZ-EPT
	 	Czech Republic	 	12 Dec 2006	 	06849951.6	 	29 Oct 2008	 	1984344	 	26 Sep 2012	 	1984344
	 LEX-1002-DE-EPT
	 	Germany	 	12 Dec 2006	 	06849951.6	 	29 Oct 2008	 	1984344	 	26 Sep 2012	 	602006032204.6
	 LEX-1002-DK-EPT
	 	Denmark	 	12 Dec 2006	 	06849951.6	 	29 Oct 2008	 	1984344	 	26 Sep 2012	 	1984344
	 LEX-1002-EA-EAT
	 	Eurasian Procedure	 	12 Dec 2006	 	200870127	 		 		 		 	
	 LEX-1002-EP-EPT
	 	European Procedure (Patents)	 	12 Dec 2006	 	06849951.6	 	29 Oct 2008	 	1984344	 	26 Sep 2012	 	1984344
	 LEX-1002-EP-ETD
	 	European Procedure (Patents)	 	24 Jun 2011	 	11005146.3	 	16 Nov 2011	 	2386547	 		 	
	 LEX-1002-ES-EPT
	 	Spain	 	12 Dec 2006	 	06849951.6	 	29 Oct 2008	 	1984344	 	26 Sep 2012	 	1984344
	 LEX-1002-FR-EPT
	 	France	 	12 Dec 2006	 	06849951.6	 	29 Oct 2008	 	1984344	 	26 Sep 2012	 	1984344
	 LEX-1002-GB-EPT
	 	United Kingdom	 	12 Dec 2006	 	06849951.6	 	29 Oct 2008	 	1984344	 	26 Sep 2012	 	1984344
	 LEX-1002-GR-EPT
	 	Greece	 	12 Dec 2006	 	06849951.6	 	29 Oct 2008	 	1984344	 	26 Sep 2012	 	3079551
	 LEX-1002-HK-FPD
	 	Hong Kong	 	09 Sep 2013	 	13110408.0	 	13 Dec 2013	 	1183027A	 		 	
	 LEX-1002-HK-FPR
	 	Hong Kong	 	11 Mar 2009	 	09102308.4	 	24 Jul 2009	 	1124841A	 	12 Jul 2013	 	HK1124841
	 LEX-1002-HU-EPT
	 	Hungary	 	12 Dec 2006	 	06849951.6	 	29 Oct 2008	 	1984344	 	26 Sep 2012	 	1984344
	 LEX-1002-IE-EPT
	 	Ireland	 	12 Dec 2006	 	06849951.6	 	29 Oct 2008	 	1984344	 	26 Sep 2012	 	1984344
	 LEX-1002-IL-PCT
	 	Israel	 	12 Dec 2006	 	191998	 		 		 		 	
	 LEX-1002-IN-PCT
	 	India	 	12 Dec 2006	 	05368/DELNP/2008	 		 		 		 	
	 LEX-1002-IT-EPT
	 	Italy	 	12 Dec 2006	 	06849951.6	 	29 Oct 2008	 	1984344	 	26 Sep 2012	 	1984344
	 LEX-1002-JP-PCT
	 	Japan	 	12 Dec 2006	 	2008-548561	 	11 Jun 2009	 	2009-522265	 	28 Feb 2014	 	5483883
	 LEX-1002-KR-PCT
	 	South Korea / Republic of Korea	 	12 Dec 2006	 	10-2008-7015697	 		 		 	03 Feb 2014	 	10-1360621
	 LEX-1002-MX-PCT    
	 	Mexico	 	12 Dec 2006	 	MX/a/2008/008483	 		 		 	09 Mar 2011	 	284609

															
	 LEX-1002-NL-EPT
	 	Netherlands	 	12 Dec 2006	 	06849951.6	 	29 Oct 2008	 	1984344	 	26 Sep 2012	 	1984344
	 LEX-1002-NO-PCT
	 	Norway	 	12 Dec 2006	 	20083324	 		 		 		 	
	 LEX-1002-NZ-PCT
	 	New Zealand	 	12 Dec 2006	 	568946	 		 		 	06 Nov 2010	 	568946
	 LEX-1002-PL-EPT
	 	Poland	 	12 Dec 2006	 	06849951.6	 	29 Oct 2008	 	1984344	 	26 Sep 2012	 	1984344
	 LEX-1002-PT-EPT
	 	Portugal	 	12 Dec 2006	 	06849951.6	 	29 Oct 2008	 	1984344	 	26 Sep 2012	 	1984344
	 LEX-1002-RO-EPT
	 	Romania	 	12 Dec 2006	 	06849951.6	 	29 Oct 2008	 	1984344	 	26 Sep 2012	 	1984344
	 LEX-1002-SE-EPT
	 	Sweden	 	12 Dec 2006	 	06849951.6	 	29 Oct 2008	 	1984344	 	26 Sep 2012	 	1984344
	 LEX-1002-SG-PCT
	 	Singapore	 	12 Dec 2006	 	200804766-4	 		 		 	13 Aug 2010	 	143823
	 LEX-1002-TR-EPT
	 	Turkey	 	12 Dec 2006	 	06849951.6	 	29 Oct 2008	 	1984344	 	26 Sep 2012	 	1984344
	 LEX-1002-UA-PCT
	 	Ukraine	 	12 Dec 2006	 	200809740	 		 		 	26 Dec 2011	 	96936
	 LEX-1002-US-CNT
	 	United States Of America	 	30 Mar 2010	 	12/750,278	 	04 Nov 2010	 	US-2010-0280054-A1	 	22 Nov 2011	 	8,063,057
	 LEX-1002-US-CNT[2]
	 	United States Of America	 	07 Nov 2011	 	13/290,261	 	21 Jun 2012	 	US 2012/0157484 A1	 	14 Jan 2014	 	8,629,156
	 LEX-1002-US-NP
	 	United States Of America	 	12 Dec 2006	 	11/638,677	 	16 Aug 2007	 	US-2007-0191370-A1	 	25 May 2010	 	7,723,345
	 LEX-1002-ZA-PCT
	 	South Africa	 	12 Dec 2006	 	2008/05192	 		 		 	25 Nov 2009	 	2008/05192
	 LEX-1004-US-CIP
	 	United States Of America	 	24 Oct 2008	 	12/257,558	 	07 May 2009	 	US-2009-0118505-A1	 	01 Mar 2011	 	7,897,763
	 LEX-1004-US-CNT
	 	United States Of America	 	10 Feb 2011	 	13/024,469	 	02 Jun 2011	 	US-2011-0130564-A1	 	28 May 2013	 	8,450,532
	 LEX-1004-US-NP
	 	United States Of America	 	28 Dec 2006	 	11/647,517	 	19 Feb 2009	 	US-2009-0048280-A1	 	21 Dec 2010	 	7,855,291
	 LEX-1005-AR-NP
	 	Argentina	 	11 Dec 2007	 	P070105537	 	25 Mar 2009	 	AR064279 A1	 		 	
	 LEX-1005-AU-PCT
	 	Australia	 	11 Dec 2007	 	2007333120	 		 		 	23 May 2013	 	2007333120
	 LEX-1005-BR-PCT
	 	Brazil	 	11 Dec 2007	 	PI0720270-9	 	29 Jul 2014	 	2273	 		 	
	 LEX-1005-CA-PCT
	 	Canada	 	11 Dec 2007	 	2,672,233	 		 		 		 	
	 LEX-1005-CN-DIV
	 	China	 	09 May 2014	 	201410196723.3	 	17 Sep 2014	 	CN 104045626A	 		 	
	 LEX-1005-CN-NP
	 	China	 	30 May 2008	 	200810108453.0	 	02 Dec 2009	 	CN 101591332A	 	16 Apr 2014	 	ZL200810108453.0
	 LEX-1005-EA-EAT
	 	Eurasian Procedure	 	11 Dec 2007	 	200970575	 		 		 	30 May 2013	 	018150
	 LEX-1005-EP-EPT
	 	European Procedure (Patents)	 	11 Dec 2007	 	07865487.8	 	26 Aug 2009	 	2091940	 		 	
	 LEX-1005-EP-ETD
	 	European Procedure (Patents)	 	04 Feb 2013	 	13153803.5	 	08 May 2013	 	2589600	 		 	
	 LEX-1005-HK-FPR
	 	Hong Kong	 	16 Mar 2010	 	10102736.3	 	18 Jun 2010	 	1135987A	 		 	
	 LEX-1005-IL-PCD    
	 	Israel	 		 		 		 		 		 	

  
 2 

															
	 LEX-1005-IL-PCT
	 	Israel	 	11 Dec 2007	 	198806	 		 		 		 	
	 LEX-1005-IN-PCT
	 	India	 	11 Dec 2007	 	3374/CHENP/2009	 		 		 		 	
	 LEX-1005-JP-PCT
	 	Japan	 	11 Dec 2007	 	2009-541514	 	22 Apr 2010	 	2010-512416	 	13 Sep 2013	 	5361734
	 LEX-1005-KR-PCT
	 	South Korea / Republic of Korea	 	11 Dec 2007	 	10-2009-7012100	 		 		 		 	
	 LEX-1005-MX-PCT
	 	Mexico	 	11 Dec 2007	 	MX/a/2009/006195	 		 		 	15 Dec 2011	 	293795
	 LEX-1005-NO-PCT
	 	Norway	 	11 Dec 2007	 	20092639	 		 		 		 	
	 LEX-1005-NZ-PCT
	 	New Zealand	 	11 Dec 2007	 	577004	 	28 Oct 2011	 	577004	 	07 Feb 2012	 	577004
	 LEX-1005-RU-EAT
	 	Russian Federation	 	11 Dec 2007	 	200970575	 		 		 	30 May 2013	 	018150
	 LEX-1005-SG-PCT
	 	Singapore	 	11 Dec 2007	 	200903523-9	 		 		 	15 Apr 2011	 	152707
	 LEX-1005-TW-NP
	 	Taiwan	 	10 Dec 2007	 	96147104	 	01 Aug 2008	 	200831102	 	21 Oct 2013	 	I412365
	 LEX-1005-UA-PCT
	 	Ukraine	 	11 Dec 2007	 	200907262	 		 		 	01 Aug 2012	 	99270
	 LEX-1005-US-CNT
	 	United States Of America	 	20 May 2009	 	12/468,974	 	19 Nov 2009	 	US-2009-0286817-A1	 	04 May 2010	 	7,709,493
	 LEX-1005-US-CNT[2]
	 	United States Of America	 	05 Apr 2010	 	12/754,341	 	09 Dec 2010	 	US-2010-0311764-A1	 	28 Jun 2011	 	7,968,559
	 LEX-1005-US-CNT[3]
	 	United States Of America	 	17 Jun 2011	 	13/162,989	 	16 Feb 2012	 	US-2012-0041008-A1	 	08 Jul 2014	 	8,772,482
	 LEX-1005-US-CNT[4]
	 	United States Of America	 	20 Jun 2014	 	14/310,031	 		 		 		 	
	 LEX-1005-US-NP
	 	United States Of America	 	11 Dec 2007	 	11/954,000	 	26 Jun 2008	 	US-2008-0153852-A1	 	30 Jun 2009	 	7,553,840
	 LEX-1005-ZA-PCT
	 	South Africa	 	11 Dec 2007	 	2009/03367	 		 		 	25 Aug 2010	 	2009/03367
	 LEX-1006-US-NP
	 	United States Of America	 	24 Jun 2008	 	12/144,821	 	01 Jan 2009	 	US-2009-0005381-A1	 		 	
	 LEX-1007-AU-PCT
	 	Australia	 	24 Jun 2008	 	2008268409	 		 		 	20 Mar 2014	 	2008268409
	 LEX-1007-CA-PCT
	 	Canada	 	24 Jun 2008	 	2,691,005	 		 		 		 	
	 LEX-1007-EP-EPT
	 	European Procedure (Patents)	 	24 Jun 2008	 	08771805.2	 	07 Apr 2010	 	2170335	 		 	
	 LEX-1007-KR-PCT
	 	South Korea / Republic of Korea	 	24 Jun 2008	 	10-2009-7026993	 		 		 		 	
	 LEX-1007-US-NP
	 	United States Of America	 	24 Jun 2008	 	12/144,953	 	01 Jan 2009	 	US-2009-0005382-A1	 	10 Jan 2012	 	8,093,291
	 LEX-1008-US-CNT
	 	United States Of America	 	14 Jan 2011	 	13/006,592	 	12 May 2011	 	US-2011-0112094-A1	 	02 Apr 2013	 	8,410,121
	 LEX-1008-US-NP
	 	United States Of America	 	09 Jul 2008	 	12/169,815	 	26 Feb 2009	 	US-2009-0054308-A1	 	25 Jan 2011	 	7,875,622
	 LEX-1009-AR-NP    
	 	Argentina	 	25 Sep 2008	 	080104181	 		 		 		 	

  
 3 

															
	 LEX-1009-AT-EPT
	 	Austria	 	25 Sep 2008	 	08834252.2	 		 		 	24 Jul 2013	 	2203444
	 LEX-1009-AU-PCT
	 	Australia	 	25 Sep 2008	 	2008304439	 		 		 	30 Jan 2014	 	2008304439
	 LEX-1009-BE-EPT
	 	Belgium	 	25 Sep 2008	 	08834252.2	 		 		 	24 Jul 2013	 	2203444
	 LEX-1009-BG-EPT
	 	Bulgaria	 	25 Sep 2008	 	08834252.2	 		 		 	24 Jul 2013	 	2203444
	 LEX-1009-BR-PCT
	 	Brazil	 	25 Sep 2008	 	PI0817270-6	 		 		 		 	
	 LEX-1009-CA-PCT
	 	Canada	 	25 Sep 2008	 	2,700,835	 		 		 		 	
	 LEX-1009-CH-EPT
	 	Switzerland	 	25 Sep 2008	 	08834252.2	 		 		 	24 Jul 2013	 	2203444
	 LEX-1009-CL-NP
	 	Chile	 	26 Sep 2008	 	2880-2008	 	27 Mar 2009	 		 		 	
	 LEX-1009-CN-PCT
	 	China	 	25 Sep 2008	 	200880108684.x	 	18 Aug 2010	 	CN 101809018A	 	06 Feb 2013	 	ZL200880108684.X
	 LEX-1009-CZ-EPT
	 	Czech Republic	 	25 Sep 2008	 	08834252.2	 		 		 	24 Jul 2013	 	2203444
	 LEX-1009-DE-EPT
	 	Germany	 	25 Sep 2008	 	08834252.2	 		 		 	24 Jul 2013	 	602008026290.1
	 LEX-1009-DK-EPT
	 	Denmark	 	25 Sep 2008	 	08834252.2	 		 		 	24 Jul 2013	 	2203444
	 LEX-1009-EA-EAT
	 	Eurasian Procedure	 	25 Sep 2008	 	201070410	 		 		 	30 Nov 2012	 	017275
	 LEX-1009-EP-EPT
	 	European Procedure (Patents)	 	25 Sep 2008	 	08834252.2	 	07 Jul 2010	 	2203444	 	24 Jul 2013	 	2203444
	 LEX-1009-ES-EPT
	 	Spain	 	25 Sep 2008	 	08834252.2	 		 		 	24 Jul 2013	 	2203444
	 LEX-1009-FR-EPT
	 	France	 	25 Sep 2008	 	08834252.2	 		 		 	24 Jul 2013	 	2203444
	 LEX-1009-GB-EPT
	 	United Kingdom	 	25 Sep 2008	 	08834252.2	 		 		 	24 Jul 2013	 	2203444
	 LEX-1009-GR-EPT
	 	Greece	 	25 Sep 2008	 	08834252.2	 	07 Jul 2010	 	2203444	 	24 Jul 2013	 	3081930
	 LEX-1009-HK-FPR
	 	Hong Kong	 	10 Dec 2010	 	10111537.5	 	25 Mar 2011	 	1145023B	 	12 Jul 2013	 	HK1145023
	 LEX-1009-HU-EPT
	 	Hungary	 	25 Sep 2008	 	08834252.2	 		 		 	24 Jul 2013	 	2203444
	 LEX-1009-IE-EPT
	 	Ireland	 	25 Sep 2008	 	08834252.2	 		 		 	24 Jul 2013	 	2203444
	 LEX-1009-IL-PCT
	 	Israel	 	25 Sep 2008	 	204373	 	31 Dec 2013	 		 	01 Apr 2014	 	204373
	 LEX-1009-IN-PCT
	 	India	 	25 Sep 2008	 	2222/DELNP/2010	 	14 Oct 2011	 	17394	 		 	
	 LEX-1009-IT-EPT
	 	Italy	 	25 Sep 2008	 	08834252.2	 		 		 	24 Jul 2013	 	2203444
	 LEX-1009-JP-PCT
	 	Japan	 	25 Sep 2008	 	2010-527125	 	24 Dec 2010	 	2010-540551	 		 	
	 LEX-1009-KR-PCT
	 	South Korea / Republic of Korea	 	25 Sep 2008	 	10-2010-7006616	 		 		 		 	
	 LEX-1009-MX-PCT
	 	Mexico	 	25 Sep 2008	 	MX/a/2010/003326	 		 		 	13 Dec 2012	 	306073
	 LEX-1009-NL-EPT
	 	Netherlands	 	25 Sep 2008	 	08834252.2	 		 		 	24 Jul 2013	 	2203444
	 LEX-1009-NO-EPT
	 	Norway	 	25 Sep 2008	 	08834252.2	 		 		 	24 Jul 2013	 	2203444
	 LEX-1009-NZ-PCT
	 	New Zealand	 	25 Sep 2008	 	583808	 		 		 	07 May 2012	 	583808
	 LEX-1009-PL-EPT
	 	Poland	 	25 Sep 2008	 	08834252.2	 		 		 	24 Jul 2013	 	2203444
	 LEX-1009-PT-EPT
	 	Portugal	 	25 Sep 2008	 	08834252.2	 		 		 	24 Jul 2013	 	2203444
	 LEX-1009-RU-EAT    
	 	Russian Federation	 	25 Sep 2008	 	201070410	 		 		 	30 Nov 2012	 	017275

  
 4 

															
	 LEX-1009-SE-EPT
	 	Sweden	 	25 Sep 2008	 	08834252.2	 		 		 	24 Jul 2013	 	2203444
	 LEX-1009-SG-PCT
	 	Singapore	 	25 Sep 2008	 	201002123-6	 		 		 	28 Sep 2012	 	160104
	 LEX-1009-TH-NP
	 	Thailand	 	12 Sep 2008	 	0801004715	 	30 Jan 2012	 	111683	 		 	
	 LEX-1009-TR-EPT
	 	Turkey	 	25 Sep 2008	 	08834252.2	 		 		 	24 Jul 2013	 	2203444
	 LEX-1009-TW-NP
	 	Taiwan	 	19 Sep 2008	 	97136105	 	01 Jun 2009	 	200922934	 	01 Jun 2014	 	I439457
	 LEX-1009-UA-PCT
	 	Ukraine	 	25 Sep 2008	 	201005125	 		 		 	10 Jun 2013	 	102079
	 LEX-1009-US-CNT
	 	United States Of America	 	01 Jun 2012	 	13/486,103	 	03 Jan 2013	 	US-2013-0005754-A1	 	18 Feb 2014	 	8,653,094
	 LEX-1009-US-NP
	 	United States Of America	 	25 Sep 2008	 	12/237,455	 	02 Apr 2009	 	US-2009-0088447-A1	 	05 Jun 2012	 	8,193,204
	 LEX-1009-ZA-PCT
	 	South Africa	 	25 Sep 2008	 	2010/01750	 		 		 	25 May 2011	 	2010/01750
	 LEX-1010-AU-PCT
	 	Australia	 	22 Aug 2008	 	2008293679	 		 		 	24 Dec 2013	 	2008293679
	 LEX-1010-BR-PCT
	 	Brazil	 	22 Aug 2008	 	PI0815754-5	 		 		 		 	
	 LEX-1010-CA-PCT
	 	Canada	 	22 Aug 2008	 	2,697,368	 		 		 		 	
	 LEX-1010-CN-PCT
	 	China	 	22 Aug 2008	 	200880104288.X	 	11 Aug 2010	 	CN 101801384A	 	21 Mar 2012	 	ZL200880104288.X
	 LEX-1010-EP-EPT
	 	European Procedure (Patents)	 	22 Aug 2008	 	08828111.8	 	26 May 2010	 	2187887	 		 	
	 LEX-1010-HK-FPR
	 	Hong Kong	 	05 Nov 2010	 	10110369.0	 		 		 	07 Sep 2012	 	1143749
	 LEX-1010-IL-PCD
	 	Israel	 	20 May 2013	 	226441	 	30 Jun 2014	 		 		 	
	 LEX-1010-IL-PCT
	 	Israel	 	22 Aug 2008	 	203669	 		 		 		 	
	 LEX-1010-IN-PCT
	 	India	 	22 Aug 2008	 	1490/DELNP/2010	 	06 Aug 2010	 	32/2010	 		 	
	 LEX-1010-JP-PCT
	 	Japan	 	22 Aug 2008	 	2010-522057	 	02 Dec 2010	 	2010-536879	 	06 Jun 2014	 	5553752
	 LEX-1010-KR-PCT
	 	South Korea / Republic of Korea	 	22 Aug 2008	 	10-2010-7003916	 		 		 		 	
	 LEX-1010-MX-PCT
	 	Mexico	 	22 Aug 2008	 	MX/a/2010/001938	 		 		 		 	
	 LEX-1010-NZ-PCT
	 	New Zealand	 	22 Aug 2008	 	583017	 	24 Feb 2012	 	583017	 	05 Jun 2012	 	583017
	 LEX-1010-RU-PCT
	 	Russian Federation	 	22 Aug 2008	 	2010111125	 		 		 	20 Sep 2013	 	2493156
	 LEX-1010-US-CNT
	 	United States Of America	 	15 Jun 2011	 	13/160,678	 	08 Dec 2011	 	US-2011-0301349-A1	 	05 Nov 2013	 	8,575,362
	 LEX-1010-US-DIV
	 	United States Of America	 	26 Mar 2010	 	12/732,311	 	23 Sep 2010	 	US-2010-0240906-A1	 	28 Jun 2011	 	7,968,729
	 LEX-1010-ZA-PCT
	 	South Africa	 	22 Aug 2008	 	2010/00785	 		 		 	28 Apr 2011	 	2010/00785
	 LEX-1305-US-PCT
	 	United States Of America	 	04 Nov 2010	 	13/505,895	 	13 Dec 2012	 	US-2012-0316171-A1	 		 	
	 LEX-1308-WO-PCT
	 	International Procedure	 	09 Feb 2011	 	PCT/US2011/024141	 	18 Aug 2001	 	WO 2011/100285	 		 	
	 LEX-1313-AU-PCT    
	 	Australia	 	16 Oct 2012	 	2012326383	 		 		 		 	

  
 5 

															
	 LEX-1313-BR-PCT
	 	Brazil	 	16 Oct 2012	 	BR112014009308-3	 		 		 		 	
	 LEX-1313-CA-PCT
	 	Canada	 	16 Oct 2012	 	2,851,862	 		 		 		 	
	 LEX-1313-CN-PCT
	 	China	 	16 Oct 2012	 	201280051029.1	 	13 Aug 2014	 	CN 103987381A	 		 	
	 LEX-1313-EP-EPT
	 	European Procedure (Patents)	 	16 Oct 2012	 	12780617.2	 	16 Jul 2014	 	2753306	 		 	
	 LEX-1313-HK-FPR
	 	Hong Kong	 	05 Sep 2014	 	14109067.3	 		 		 		 	
	 LEX-1313-IL-PCT
	 	Israel	 	16 Oct 2012	 	PCT/US2012/060338	 		 		 		 	
	 LEX-1313-IN-PCT
	 	India	 	16 Oct 2012	 	3600/DELNP/2014	 		 		 		 	
	 LEX-1313-JP-PCT
	 	Japan	 	16 Oct 2012	 	2014-535988	 		 		 		 	
	 LEX-1313-KR-PCT
	 	South Korea / Republic of Korea	 	16 Oct 2012	 	PCT/US2012/060338	 		 		 		 	
	 LEX-1313-MX-PCT
	 	Mexico	 	16 Oct 2012	 	MX/a/2014/004603	 		 		 		 	
	 LEX-1313-NZ-PCT
	 	New Zealand	 	16 Oct 2012	 	623423	 		 		 		 	
	 LEX-1313-RU-PCT
	 	Russian Federation	 	16 Oct 2012	 	2014119866	 		 		 		 	
	 LEX-1313-SG-PCT
	 	Singapore	 	16 Oct 2012	 	11201401583Y	 		 		 		 	
	 LEX-1313-TH-PCT
	 	Thailand	 	16 Oct 2012	 	1401002078	 		 		 		 	
	 LEX-1313-UA-PCT
	 	Ukraine	 	16 Oct 2012	 	a 2014 05227	 		 		 		 	
	 LEX-1313-US-NP
	 	United States Of America	 	16 Oct 2012	 	13/652,527	 	04 Jul 2013	 	US 2013/0172376 A1	 		 	
	 LEX-1313-ZA-PCT
	 	South Africa	 	16 Oct 2012	 	PCT/US2012/060338	 		 		 		 	
	 LEX-1314-AR-NP
	 	Argentina	 	04 Nov 2011	 	20110104110	 	20 Mar 2013	 	AR083755 A1	 		 	
	 LEX-1314-AU-PCT
	 	Australia	 	03 Nov 2011	 	2011323302	 		 		 		 	
	 LEX-1314-BR-PCT
	 	Brazil	 	03 Nov 2011	 	BR112013011015-5	 		 		 		 	
	 LEX-1314-CA-PCT
	 	Canada	 	03 Nov 2011	 	2,816,963	 		 		 		 	
	 LEX-1314-EP-EPT
	 	European Procedure (Patents)	 	03 Nov 2011	 	11787757.1	 	11 Sep 2013	 	2635569	 		 	
	 LEX-1314-HK-FPR
	 	Hong Kong	 	26 Aug 2013	 	13109961.1	 	06 Dec 2013	 	1182698A	 		 	
	 LEX-1314-IN-PCT
	 	India	 	03 Nov 2011	 	3664/DELNP/2013	 		 		 		 	
	 LEX-1314-JP-PCT
	 	Japan	 	03 Nov 2011	 	2013-537814	 	14 Nov 2013	 	2013-541589	 		 	
	 LEX-1314-KR-PCT
	 	South Korea / Republic of Korea	 	03 Nov 2011	 	10-2013-7014387	 		 		 		 	
	 LEX-1314-MX-PCT
	 	Mexico	 	03 Nov 2011	 	MX/a/2013/004921	 		 		 		 	
	 LEX-1314-NZ-PCT
	 	New Zealand	 	03 Nov 2011	 	609919	 		 		 		 	
	 LEX-1314-RU-PCT
	 	Russian Federation	 	03 Nov 2011	 	2013125756	 		 		 		 	
	 LEX-1314-SG-PCT    
	 	Singapore	 	03 Nov 2011	 	201303215-6	 		 		 		 	

  
 6 

															
	 LEX-1314-TW-NP
	 	Taiwan	 	20 Oct 2011	 	100138117	 	16 Nov 2012	 	201245183	 		 	
	 LEX-1314-UA-PCT
	 	Ukraine	 	03 Nov 2011	 	201307066	 		 		 		 	
	 LEX-1314-US-NP
	 	United States Of America	 	03 Nov 2011	 	13/288,366	 	17 May 2012	 	US-2012-0122904-A1	 	08 Jul 2014	 	8,772,483
	 LEX-1314-ZA-PCT
	 	South Africa	 	03 Nov 2011	 	2013/03049	 		 		 		 	
	 LEX-1327-WO-PCT
	 	International Procedure	 	28 Mar 2013	 	PCT/US2013/034314	 	03 Oct 2013	 	WO 2013/148978	 		 	
	 LEX-1328-WO-PCT    
	 	International Procedure	 	25 Nov 2013	 	PCT/2013/071678	 	30 May 2014	 	WO 2014/082034	 		 	

  
 7 

 LG421 
  

															
	 Case Reference
	 	 Country
	 	 Filing
	 	 Filing Number
	 	 Publication
	 	 Publication
Number
	 	 Grant
	 	 Grant Number

	 LEX-1000-AR-NP
	 	Argentina	 	28 Sep 2007	 	P070104306	 	23 Dec 2008	 	AR063047A1	 		 	
	 LEX-1000-AT-EPT
	 	Austria	 	27 Sep 2007	 	07843301.8	 	19 Aug 2009	 	2089361	 	26 Jan 2011	 	2089361
	 LEX-1000-AT-ETD
	 	Austria	 	27 Sep 2007	 	10194063.3	 		 		 	16 Apr 2014	 	2308841
	 LEX-1000-AU-PCT
	 	Australia	 	27 Sep 2007	 	2007304971	 		 		 	03 Oct 2013	 	2007304971
	 LEX-1000-BE-EPT
	 	Belgium	 	27 Sep 2007	 	07843301.8	 	19 Aug 2009	 	2089361	 	26 Jan 2011	 	2089361
	 LEX-1000-BE-ETD
	 	Belgium	 	27 Sep 2007	 	10194063.3	 		 		 	16 Apr 2014	 	2308841
	 LEX-1000-BR-PCT
	 	Brazil	 	27 Sep 2007	 	PI0717156-0	 	15 Oct 2013	 	2232	 		 	
	 LEX-1000-CA-PCT
	 	Canada	 	27 Sep 2007	 	2,664,688	 		 		 		 	
	 LEX-1000-CH-EPT
	 	Switzerland	 	27 Sep 2007	 	07843301.8	 	19 Aug 2009	 	2089361	 	26 Jan 2011	 	2089361
	 LEX-1000-CH-ETD
	 	Switzerland	 	27 Sep 2007	 	10194063.3	 		 		 	16 Apr 2014	 	2308841
	 LEX-1000-CN-DIV
	 	China	 	14 Mar 2013	 	201310082020.3	 	21 Aug 2013	 	CN 103254119A	 		 	
	 LEX-1000-CN-NP
	 	China	 	02 Apr 2008	 	200810090073.9	 	14 Jan 2009	 	CN101343296A	 	10 Apr 2013	 	ZL200810090073.9
	 LEX-1000-CZ-EPT
	 	Czech Republic	 	27 Sep 2007	 	07843301.8	 	19 Aug 2009	 	2089361	 	26 Jan 2011	 	2089361
	 LEX-1000-CZ-ETD
	 	Czech Republic	 	27 Sep 2007	 	10194063.3	 		 		 	16 Apr 2014	 	2308841
	 LEX-1000-DE-EPT
	 	Germany	 	27 Sep 2007	 	07843301.8	 	19 Aug 2009	 	2089361	 	26 Jan 2011	 	602007012292.9
	 LEX-1000-DE-ETD
	 	Germany	 	27 Sep 2007	 	10194063.3	 		 		 	16 Apr 2014	 	2308841
	 LEX-1000-DK-EPT
	 	Denmark	 	27 Sep 2007	 	07843301.8	 	19 Aug 2009	 	2089361	 	26 Jan 2011	 	2089361
	 LEX-1000-DK-ETD
	 	Denmark	 	27 Sep 2007	 	10194063.3	 		 		 	16 Apr 2014	 	2308841
	 LEX-1000-EA-EAT
	 	Eurasian Procedure	 	27 Sep 2007	 	200970337	 		 		 	30 May 2012	 	016511
	 LEX-1000-EP-EPT
	 	European Procedure (Patents)	 	27 Sep 2007	 	07843301.8	 	19 Aug 2009	 	2089361	 	26 Jan 2011	 	2089361
	 LEX-1000-EP-ETD    
	 	European Procedure (Patents)	 	27 Sep 2007	 	10194063.3	 	13 Apr 2011	 	2308841	 	16 Apr 2014	 	2308841

  
 8 

															
	 LEX-1000-ES-EPT
	 	Spain	 	27 Sep 2007	 	07843301.8	 	19 Aug 2009	 	2089361	 	26 Jan 2011	 	2089361
	 LEX-1000-ES-ETD
	 	Spain	 	27 Sep 2007	 	10194063.3	 		 		 	16 Apr 2014	 	2308841
	 LEX-1000-FR-EPT
	 	France	 	27 Sep 2007	 	07843301.8	 	19 Aug 2009	 	2089361	 	26 Jan 2011	 	2089361
	 LEX-1000-FR-ETD
	 	France	 	27 Sep 2007	 	10194063.3	 		 		 	16 Apr 2014	 	2308841
	 LEX-1000-GB-EPT
	 	United Kingdom	 	27 Sep 2007	 	07843301.8	 	19 Aug 2009	 	2089361	 	26 Jan 2011	 	2089361
	 LEX-1000-GB-ETD
	 	United Kingdom	 	27 Sep 2007	 	10194063.3	 		 		 	16 Apr 2014	 	2308841
	 LEX-1000-GR-EPT
	 	Greece	 	27 Sep 2007	 	07843301.8	 	19 Aug 2009	 	2089361	 	26 Jan 2011	 	3074740
	 LEX-1000-GR-ETD
	 	Greece	 	27 Sep 2007	 	10194063.3	 		 		 	16 Apr 2014	 	2308841
	 LEX-1000-HK-FPD
	 	Hong Kong	 	04 Sep 2013	 	13110285.8	 	13 Dec 2013	 	1183020A	 		 	
	 LEX-1000-HK-FPR
	 	Hong Kong	 	19 Mar 2009	 	09102667.9	 	24 Jul 2009	 	1124863A	 	10 Jan 2014	 	HK1124863
	 LEX-1000-HU-EPT
	 	Hungary	 	27 Sep 2007	 	07843301.8	 	19 Aug 2009	 	2089361	 	26 Jan 2011	 	2089361
	 LEX-1000-HU-ETD
	 	Hungary	 	27 Sep 2007	 	10194063.3	 		 		 	16 Apr 2014	 	2308841
	 LEX-1000-IE-EPT
	 	Ireland	 	27 Sep 2007	 	07843301.8	 	19 Aug 2009	 	2089361	 	26 Jan 2011	 	2089361
	 LEX-1000-IE-ETD
	 	Ireland	 	27 Sep 2007	 	10194063.3	 		 		 	16 Apr 2014	 	2308841
	 LEX-1000-IL-PCT
	 	Israel	 	27 Sep 2007	 	197836	 	30 Jan 2014	 		 	01 May 2014	 	197836
	 LEX-1000-IN-PCT
	 	India	 	27 Sep 2007	 	00609/MUMNP/2009	 		 		 	14 Feb 2014	 	258913
	 LEX-1000-IT-EPT
	 	Italy	 	27 Sep 2007	 	07843301.8	 	19 Aug 2009	 	2089361	 	26 Jan 2011	 	2089361
	 LEX-1000-IT-ETD
	 	Italy	 	27 Sep 2007	 	10194063.3	 		 		 	16 Apr 2014	 	2308841
	 LEX-1000-JP-PCD
	 	Japan	 	20 Nov 2012	 	2012-254023	 	02 May 2013	 	2013-079243	 		 	
	 LEX-1000-JP-PCT
	 	Japan	 	27 Sep 2007	 	2009-530593	 	18 Feb 2010	 	2010-504998	 	07 Jun 2013	 	5283625
	 LEX-1000-KR-PCD
	 	South Korea / Republic of Korea	 		 		 		 		 		 	
	 LEX-1000-KR-PCT
	 	South Korea / Republic of Korea	 	27 Sep 2007	 	10-2009-7008685	 		 		 		 	
	 LEX-1000-MX-PCT
	 	Mexico	 	27 Sep 2007	 	MX/a/2009/003305	 		 		 	29 Jun 2011	 	287903
	 LEX-1000-NL-EPT
	 	Netherlands	 	27 Sep 2007	 	07843301.8	 	19 Aug 2009	 	2089361	 	26 Jan 2011	 	2089361
	 LEX-1000-NL-ETD    
	 	Netherlands	 	27 Sep 2007	 	10194063.3	 		 		 	16 Apr 2014	 	2308841

  
 9 

															
	 LEX-1000-NO-PCT
	 	Norway	 	27 Sep 2007	 	20091700	 		 		 		 	
	 LEX-1000-NZ-PCT
	 	New Zealand	 	27 Sep 2007	 	575811	 	28 Oct 2011	 	575811	 	07 Feb 2012	 	575811
	 LEX-1000-PL-EPT
	 	Poland	 	27 Sep 2007	 	07843301.8	 	19 Aug 2009	 	2089361	 	26 Jan 2011	 	2089361
	 LEX-1000-PL-ETD
	 	Poland	 	27 Sep 2007	 	10194063.3	 		 		 	16 Apr 2014	 	2308841
	 LEX-1000-PT-EPT
	 	Portugal	 	27 Sep 2007	 	07843301.8	 	19 Aug 2009	 	2089361	 	26 Jan 2011	 	2089361
	 LEX-1000-PT-ETD
	 	Portugal	 	27 Sep 2007	 	10194063.3	 		 		 	16 Apr 2014	 	2308841
	 LEX-1000-RO-EPT
	 	Romania	 	27 Sep 2007	 	07843301.8	 	19 Aug 2009	 	2089361	 	26 Jan 2011	 	2089361
	 LEX-1000-RO-ETD
	 	Romania	 	27 Sep 2007	 	10194063.3	 		 		 	16 Apr 2014	 	2308841
	 LEX-1000-RU-EAT
	 	Russian Federation	 	27 Sep 2007	 	200970337	 		 		 	30 May 2012	 	016511
	 LEX-1000-SE-EPT
	 	Sweden	 	27 Sep 2007	 	07843301.8	 	19 Aug 2009	 	2089361	 	26 Jan 2011	 	2089361
	 LEX-1000-SE-ETD
	 	Sweden	 	27 Sep 2007	 	10194063.3	 		 		 	16 Apr 2014	 	2308841
	 LEX-1000-SG-PCT
	 	Singapore	 	27 Sep 2007	 	200902135-3	 		 		 	15 Feb 2012	 	151038
	 LEX-1000-TR-EPT
	 	Turkey	 	27 Sep 2007	 	07843301.8	 	19 Aug 2009	 	2089361	 	26 Jan 2011	 	TR 2011 02757 T4
	 LEX-1000-TR-ETD
	 	Turkey	 	27 Sep 2007	 	10194063.3	 		 		 	16 Apr 2014	 	2308841
	 LEX-1000-TW-NP
	 	Taiwan	 	19 Sep 2007	 	96134994	 	01 Jul 2008	 	200826929	 		 	
	 LEX-1000-UA-PCT
	 	Ukraine	 	27 Sep 2007	 	2009 04205	 		 		 	25 Apr 2012	 	98123
	 LEX-1000-US-CNT
	 	United States Of America	 	18 Aug 2010	 	12/858,666	 	09 Dec 2010	 	US 2010/0311673 A1	 	02 Jul 2013	 	8,476,413
	 LEX-1000-US-CNT[2]
	 	United States Of America	 	25 Jun 2013	 	13/925,981	 	15 May 2014	 	US 2014/0135277 A1	 		 	
	 LEX-1000-US-NP
	 	United States Of America	 	27 Sep 2007	 	11/862,690	 	15 May 2008	 	US-2008-0113922-A1	 	24 Aug 2010	 	7,781,577
	 LEX-1000-US-NP[2]
	 	United States Of America	 	04 Mar 2008	 	12/041,860	 	11 Sep 2008	 	US-2008-0221164-A1	 	07 Dec 2010	 	7,846,945
	 LEX-1000-ZA-PCT
	 	South Africa	 	27 Sep 2007	 	2009/02231	 		 		 	28 Jul 2010	 	2009/02231
	 LEX-1017-AR-NP
	 	Argentina	 	25 Jul 2008	 	P080103246	 	21 Oct 2009	 	AR067701 A1	 		 	
	 LEX-1017-AT-EPT
	 	Austria	 	17 Jul 2008	 	08826634.1	 	12 May 2010	 	E530558	 	25 May 2012	 	2183263
	 LEX-1017-AU-PCD    
	 	Australia	 	12 Jun 2013	 	2013206276	 		 		 		 	

  
 10 

															
	 LEX-1017-AU-PCT
	 	Australia	 	17 Jul 2008	 	2008279424	 		 		 	26 Sep 2013	 	2008279424
	 LEX-1017-BE-EPT
	 	Belgium	 	17 Jul 2008	 	08826634.1	 	12 May 2010	 	2183263	 	26 Oct 2011	 	2183263
	 LEX-1017-BR-PCT
	 	Brazil	 	17 Jul 2008	 	PI0813840-0	 		 		 		 	
	 LEX-1017-CA-PCT
	 	Canada	 	17 Jul 2008	 	2,694,029	 		 		 		 	
	 LEX-1017-CH-EPT
	 	Switzerland	 	17 Jul 2008	 	08826634.1	 	12 May 2010	 	2183263	 	26 Oct 2011	 	2183263
	 LEX-1017-CN-PCT
	 	China	 	17 Jul 2008	 	200880100489.2	 	11 Aug 2010	 	CN 101801989A	 		 	
	 LEX-1017-CZ-EPT
	 	Czech Republic	 	17 Jul 2008	 	08826634.1	 	12 May 2010	 	2183263	 	26 Oct 2011	 	2183263
	 LEX-1017-DE-EPT
	 	Germany	 	17 Jul 2008	 	08826634.1	 	12 May 2010	 	2183263	 	26 Oct 2011	 	602008010937.2
	 LEX-1017-DK-EPT
	 	Denmark	 	17 Jul 2008	 	08826634.1	 	12 May 2010	 	2183263	 	26 Oct 2011	 	2183263
	 LEX-1017-EA-EAT
	 	Eurasian Procedure	 	17 Jul 2008	 	201070186	 		 		 	28 Dec 2012	 	017411
	 LEX-1017-EP-EPT
	 	European Procedure (Patents)	 	17 Jul 2008	 	08826634.1	 	12 May 2010	 	2183263	 	26 Oct 2011	 	2183263
	 LEX-1017-ES-EPT
	 	Spain	 	17 Jul 2008	 	08826634.1	 	12 May 2010	 	2183263	 	26 Oct 2011	 	2183263
	 LEX-1017-FR-EPT
	 	France	 	17 Jul 2008	 	08826634.1	 	12 May 2010	 	2183263	 	26 Oct 2011	 	2183263
	 LEX-1017-GB-EPT
	 	United Kingdom	 	17 Jul 2008	 	08826634.1	 	12 May 2010	 	2183263	 	26 Oct 2011	 	2183263
	 LEX-1017-GR-EPT
	 	Greece	 	17 Jul 2008	 	08826634.1	 	12 May 2010	 	2183263	 	26 Oct 2011	 	3076926
	 LEX-1017-HK-FPR
	 	Hong Kong	 	12 Nov 2010	 	10110567.0	 		 		 		 	
	 LEX-1017-HU-EPT
	 	Hungary	 	17 Jul 2008	 	08826634.1	 	12 May 2010	 	2183263	 	26 Oct 2011	 	2183263
	 LEX-1017-IE-EPT
	 	Ireland	 	17 Jul 2008	 	08826634.1	 	12 May 2010	 	2183263	 	26 Oct 2011	 	2183263
	 LEX-1017-IL-PCT
	 	Israel	 	17 Jul 2008	 	203209	 	27 Feb 2014	 		 	28 May 2014	 	203209
	 LEX-1017-IN-PCT
	 	India	 	17 Jul 2008	 	493/CHENP/2010	 	23 Jul 2010	 	30/2010	 		 	
	 LEX-1017-IT-EPT
	 	Italy	 	17 Jul 2008	 	08826634.1	 	12 May 2010	 	2183263	 	26 Oct 2011	 	2183263
	 LEX-1017-JP-PCD    
	 	Japan	 	28 Aug 2013	 	2013-176646	 	09 Jan 2014	 	2014-001230	 		 	

  
 11 

															
	 LEX-1017-JP-PCT
	 	Japan	 	17 Jul 2008	 	2010-518296	 	11 Nov 2010	 	2010-534661	 		 	
	 LEX-1017-KR-PCT
	 	South Korea / Republic of Korea	 	17 Jul 2008	 	10-2010-7001659	 		 		 		 	
	 LEX-1017-MX-PCT
	 	Mexico	 	17 Jul 2008	 	MX/a/2010/000854	 		 		 	29 Feb 2012	 	296552
	 LEX-1017-NL-EPT
	 	Netherlands	 	17 Jul 2008	 	08826634.1	 	12 May 2010	 	2183263	 	26 Oct 2011	 	2183263
	 LEX-1017-NZ-PCT
	 	New Zealand	 	17 Jul 2008	 	582536	 		 		 	07 May 2012	 	582536
	 LEX-1017-PL-EPT
	 	Poland	 	17 Jul 2008	 	08826634.1	 	12 May 2010	 	2183263	 	26 Oct 2011	 	2183263
	 LEX-1017-PT-EPT
	 	Portugal	 	17 Jul 2008	 	08826634.1	 	12 May 2010	 	2183263	 	26 Oct 2011	 	2183263
	 LEX-1017-RO-EPT
	 	Romania	 	17 Jul 2008	 	08826634.1	 	12 May 2010	 	2183263	 	26 Oct 2011	 	2183263
	 LEX-1017-RU-EAT
	 	Russian Federation	 	17 Jul 2008	 	201070186	 		 		 	28 Dec 2012	 	017411
	 LEX-1017-SE-EPT
	 	Sweden	 	17 Jul 2008	 	08826634.1	 	12 May 2010	 	2183263	 	26 Oct 2011	 	2183263
	 LEX-1017-SG-PCT
	 	Singapore	 	17 Jul 2008	 	201000219-4	 		 		 	30 Apr 2012	 	158399
	 LEX-1017-TR-EPT
	 	Turkey	 	17 Jul 2008	 	08826634.1	 	12 May 2010	 	2183263	 	26 Oct 2011	 	TR 2011 12632 T4
	 LEX-1017-TW-DIV
	 	Taiwan	 	16 Aug 2013	 	102129521	 	16 Dec 2013	 	201350473	 		 	
	 LEX-1017-TW-NP
	 	Taiwan	 	21 Jul 2008	 	97127665	 	01 Apr 2009	 	200914434	 	21 Dec 2013	 	I419886
	 LEX-1017-UA-PCT
	 	Ukraine	 	17 Jul 2008	 	2010 02095	 		 		 		 	
	 LEX-1017-US-CNT
	 	United States Of America	 	11 Aug 2011	 	13/207,576	 	19 Apr 2012	 	US-2012-0095198-A1	 	23 Oct 2012	 	8,293,878
	 LEX-1017-US-NP
	 	United States Of America	 	17 Jul 2008	 	12/174,722	 	29 Jan 2009	 	US-2009-0030198-A1	 	27 Sep 2011	 	8,026,347
	 LEX-1017-ZA-PCT
	 	South Africa	 	17 Jul 2008	 	2010/00219	 		 		 	30 Mar 2011	 	2010/00219
	 LEX-1287-AR-NP
	 	Argentina	 	15 Jul 2009	 	P090102685	 	22 Sep 2010	 	AR072807 A1	 		 	
	 LEX-1287-AU-PCT
	 	Australia	 	15 Jul 2009	 	2009270973	 		 		 	15 May 2014	 	2009270973
	 LEX-1287-BR-PCT
	 	Brazil	 	15 Jul 2009	 	PI0916191-0	 		 		 		 	
	 LEX-1287-CA-PCT
	 	Canada	 	15 Jul 2009	 	2,730,931	 		 		 		 	
	 LEX-1287-CN-PCT
	 	China	 	15 Jul 2009	 	200980127924.5	 	29 Jun 2011	 	CN 102112483A	 		 	
	 LEX-1287-EP-ETD    
	 	European Procedure (Patents)	 	18 Feb 2011	 	11155100.8	 	15 Jun 2011	 	2332947	 		 	

  
 12 

															
	 LEX-1287-HK-FPR
	 	Hong Kong	 	22 Jul 2011	 	11107631.7	 	30 Mar 2012	 	1153480A	 		 	
	 LEX-1287-IL-PCT
	 	Israel	 	15 Jul 2009	 	210269	 		 		 		 	
	 LEX-1287-IN-PCT
	 	India	 	15 Jul 2009	 	504/DELNP/2011	 	10 Feb 2012	 	2264	 		 	
	 LEX-1287-JP-PCT
	 	Japan	 	15 Jul 2009	 	2011-518868	 	17 Nov 2011	 	2011-528366	 		 	
	 LEX-1287-KR-PCT
	 	South Korea / Republic of Korea	 	15 Jul 2009	 	10-2011-7001024	 		 		 		 	
	 LEX-1287-MX-PCT
	 	Mexico	 	15 Jul 2009	 	MX/a/2011/000503	 		 		 		 	
	 LEX-1287-NZ-PCT
	 	New Zealand	 	15 Jul 2009	 	590184	 		 		 	04 Jan 2013	 	590184
	 LEX-1287-RU-PCT
	 	Russian Federation	 	15 Jul 2009	 	2011105797	 		 		 	27 Jan 2014	 	2505543
	 LEX-1287-SG-PCD
	 	Singapore	 	18 Oct 2012	 	201207768-1	 	29 Nov 2012	 	185317	 		 	
	 LEX-1287-TH-NP
	 	Thailand	 	09 Jul 2009	 	0901003106	 	29 Mar 2013	 	122363	 		 	
	 LEX-1287-TW-NP
	 	Taiwan	 	01 Jul 2009	 	98122274	 	16 Feb 2010	 	201006808	 		 	
	 LEX-1287-UA-PCT
	 	Ukraine	 	15 Jul 2009	 	201101832	 		 		 		 	
	 LEX-1287-US-CNT
	 	United States Of America	 	22 Jun 2012	 	13/530,645	 	27 Jun 2013	 	US 2013/0165395 A1	 		 	
	 LEX-1287-US-NP
	 	United States Of America	 	15 Jul 2009	 	12/503,225	 	21 Jan 2010	 	US-2010-0016422-A1	 	10 Jul 2012	 	8,217,156
	 LEX-1287-ZA-PCT
	 	South Africa	 	15 Jul 2009	 	2011/00175	 		 		 	28 Mar 2012	 	2011/00175
	 LEX-1309-AR-NP
	 	Argentina	 	02 Mar 2011	 	20110100644	 	11 Apr 2012	 	AR 080444 A1	 		 	
	 LEX-1309-AU-PCT
	 	Australia	 	01 Mar 2011	 	2011223861	 		 		 		 	
	 LEX-1309-BR-PCT
	 	Brazil	 	01 Mar 2011	 	BR112012021771-2	 		 		 		 	
	 LEX-1309-CA-PCT
	 	Canada	 	01 Mar 2011	 	2,791,300	 		 		 		 	
	 LEX-1309-EP-EPT
	 	European Procedure (Patents)	 	01 Mar 2011	 	11707324.7	 	09 Jan 2013	 	2542236	 		 	
	 LEX-1309-IL-PCT
	 	Israel	 	01 Mar 2011	 	221372	 		 		 		 	
	 LEX-1309-IN-PCT
	 	India	 	01 Mar 2011	 	7336/DELNP/2012	 		 		 		 	
	 LEX-1309-JP-PCT
	 	Japan	 	01 Mar 2011	 	2012-556154	 	10 Jun 2013	 	2013-521293	 		 	
	 LEX-1309-KR-PCT    
	 	South Korea / Republic of Korea	 	01 Mar 2011	 	10-2012-7022847	 		 		 		 	

  
 13 

															
	 LEX-1309-MX-PCT
	 	Mexico	 	01 Mar 2011	 	MX/a/2012/010021	 		 		 		 	
	 LEX-1309-RU-PCT
	 	Russian Federation	 	01 Mar 2011	 	2012141893	 	10 Apr 2014	 		 		 	
	 LEX-1309-TW-NP
	 	Taiwan	 	14 Feb 2011	 	100104797	 	16 Sep 2011	 	201130486	 		 	
	 LEX-1309-UA-PCT
	 	Ukraine	 	01 Mar 2011	 	201211362	 		 		 		 	
	 LEX-1309-US-CNT
	 	United States Of America	 	10 Jun 2013	 	13/913,928	 	16 Jan 2014	 	US 2014/0018308 A1	 		 	
	 LEX-1321-AR-NP
	 	Argentina	 	04 Jan 2012	 	20120100021	 	26 Jun 2013	 	AR084781 A1	 		 	
	 LEX-1321-AU-PCT
	 	Australia	 	03 Jan 2012	 	2012204567	 		 		 		 	
	 LEX-1321-BR-PCT
	 	Brazil	 	03 Jan 2012	 	BR112013017314-9	 		 		 		 	
	 LEX-1321-CA-PCT
	 	Canada	 	03 Jan 2012	 	2,823,736	 		 		 		 	
	 LEX-1321-CN-PCT
	 	China	 	03 Jan 2012	 	201280004771.7	 	18 Dec 2013	 	CN 103458875 A	 		 	
	 LEX-1321-EP-EPT
	 	European Procedure (Patents)	 	03 Jan 2012	 	12700583.3	 	13 Nov 2013	 	2661256	 		 	
	 LEX-1321-HK-FPR
	 	Hong Kong	 	10 Jan 2014	 	14100308.1	 	04 Apr 2014	 	1187263A	 		 	
	 LEX-1321-IL-PCT
	 	Israel	 	03 Jan 2012	 	227006	 		 		 		 	
	 LEX-1321-IN-PCT
	 	India	 	03 Jan 2012	 	5656/DELNP/2013	 		 		 		 	
	 LEX-1321-JP-PCT
	 	Japan	 	03 Jan 2012	 	2013-548455	 	23 Jan 2014	 	2014-501780	 		 	
	 LEX-1321-KR-PCT
	 	South Korea / Republic of Korea	 	03 Jan 2012	 	10-2013-7020505	 		 		 		 	
	 LEX-1321-MX-PCT
	 	Mexico	 	03 Jan 2012	 	MX/a/2013/007826	 		 		 		 	
	 LEX-1321-NZ-PCT
	 	New Zealand	 	03 Jan 2012	 	612116	 		 		 		 	
	 LEX-1321-RU-PCT
	 	Russian Federation	 	03 Jan 2012	 	2013136384	 		 		 		 	
	 LEX-1321-SG-PCT
	 	Singapore	 	03 Jan 2012	 	201305204.8	 		 		 		 	
	 LEX-1321-TH-PCT
	 	Thailand	 	03 Jan 2012	 	1301003598	 		 		 		 	
	 LEX-1321-TW-NP
	 	Taiwan	 	02 Jan 2012	 	101100085	 	01 Mar 2013	 	201309345	 		 	
	 LEX-1321-UA-PCT
	 	Ukraine	 	03 Jan 2012	 	2013 09666	 		 		 		 	
	 LEX-1321-US-CNT
	 	United States Of America	 	30 May 2014	 	14/291,804	 		 		 		 	
	 LEX-1321-WO-PCT
	 	International Procedure	 	03 Jan 2012	 	PCT/US2012/020042	 	12 Jul 2012	 	WO 2012/094293	 		 	
	 LEX-1321-ZA-PCT
	 	South Africa	 	03 Jan 2012	 	2013/04694	 		 		 		 	

  
 14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}]]